1 A systematic review of antibody mediated immunity to coronaviruses : antibody kinetics , correlates of protection , and association of antibody responses with severity of disease Angkana T . Huang 1 , 2 * , Bernardo Garcia - Carreras 1 , 2 * , Matt D . T . Hitchings 1 , 2 * , Bingyi Yang 1 , 2 * , Leah C . Katzelnick 1 , 2 * , Susan M . Rattigan 1 , 2 , Brooke A . Borgert 1 , 2 , Carlos A . Moreno 1 , 2 , Benjamin D . Solomon 3 , Isabel Rodriguez - Barraquer 4 , Justin Lessler 5 , Henrik Salje 6 , Donald Burke 7 , Amy Wesolowski 5 , Derek A . T . Cummings 1 , 2 1 Department of Biology , University of Florida , USA 2 Emerging Pathogens Institute , University of Florida , USA 3 National Human Genome Research Institute , National Institutes of Health , USA 4 Division of HIV , ID , and Global Medicine , University of California , San Francisco , USA 5 Department of Epidemiology , Johns Hopkins Bloomberg School of Public Health , USA 6 Department of Genetics , University of Cambridge , Cambridge , United Kingdom 7 Department of Epidemiology , University of Pittsburgh , USA * contributed equally Corresponding Author Derek A . T . Cummings PO Box 118525 Department of Biology University of Florida Gainesville , USA Email : datc @ ufl . edu . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 2 Abstract The duration and nature of immunity generated in response to SARS - CoV - 2 infection is unknown . Many public health responses and modeled scenarios for COVID - 19 outbreaks caused by SARS - CoV - 2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time . The timescale of protection is a critical determinant of the future impact of the pathogen . The presence or absence of protective immunity due to infection or vaccination ( when available ) will affect future transmission and illness severity . The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity . Here , we review the scientific literature on antibody immunity to coronaviruses , including SARS - CoV - 2 as well as the related SARS - CoV - 1 , MERS - CoV and human endemic coronaviruses ( HCoVs ) . We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus : 1 ) antibody kinetics , 2 ) correlates of protection , 3 ) immunopathogenesis , 4 ) antigenic diversity and cross - reactivity , and 5 ) population seroprevalence . While studies of SARS - CoV - 2 are necessary to determine immune responses to it , evidence from other coronaviruses can provide clues and guide future research . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 3 Key Questions Key Questions for SARS - CoV - 2 â— What are the kinetics of immune responses to infection ? â— Do people who have more severe disease mount stronger antibody responses after infection ? â— How do antibody responses vary between different types of antibodies or as measured by different assays ? â— How does the presence of antibodies impact the clinical course and severity of the disease ? â— Is there cross - reactivity with different coronaviruses ? â— Does cross - reactivity lead to cross - protection ? â— Will infection protect you from future infection ? â— How long will immunity last ? â— What are correlates of protection ? . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 4 Introduction A pandemic of severe acute respiratory syndrome coronavirus 2 ( SARS - CoV - 2 ) is currently underway resulting in worldwide severe morbidity and mortality . Limited pre - existing immunity to this virus is thought to be responsible for the explosive increase in cases across the world . Nearly all transmission models of SARS - CoV - 2 assume that infection produces immunity to reinfection for durations of at least one year 1 â€“ 3 . This assumption is relevant to public health officials implementing and managing various non - pharmaceutical interventions , the utility of sera from infected individuals as a therapeutic 4 , and the ability for serological tests to identify those who are immune 5 . The dynamics of immunity will also affect the performance of serological testing to quantify the extent of infection in populations . However , knowledge of the dynamics and nature of immune response to SARS - CoV - 2 infection is limited , and the scientific basis for durable immunity , upon which these key public health and clinical strategies are dependent , is not well developed . Several authors have noted human experimental infection studies ( called human challenge studies ) suggesting that protection after coronavirus infections may last only 1 or 2 years 6 â€“ 9 . HCoVs have been used in human challenge experiments since shortly after their discovery in 1965 10 , 11 . These experiments , where individuals were intentionally infected with HCoV , provide some of the clearest characterization of human responses to coronaviruses and the potential for immune responses to limit infection and disease . Multiple human challenge studies measured antibody immunity before a coronavirus challenge and identified antibody responses that were associated with protection from infection , serological response or symptom 12 . The low severity of HCoV allowed for safe use of these viruses in human challenge experiments . The greater likelihood of severe illness in SARS - CoV - 2 limits the applicability of such experiments , although some have argued for their use in subsets of the population 13 . The duration of immunity of SARS - CoV - 2 will dictate the overall course of the pandemic and the post - pandemic dynamics 7 , and so an understanding of the temporal dynamics of protective immunity is critical . As with other introductions of novel pathogens 14 , explosive outbreaks of SARS - CoV - 2 across the globe may threaten its persistence by reducing the number of available hosts susceptible to infection . Immune interactions with endemic coronaviruses could theoretically affect the short - and long - term dynamics of SARS - CoV - 2 , and vice versa 15 , 16 through cross - protection or antibody - dependent enhancement 17 , but these interactions and effects are not yet understood . If SARS - CoV - 2 does become endemic , age - stratified seroprevalence studies of endemic coronaviruses may provide estimates for incidence rates in the presence of higher levels of population immunity . Here , we describe the results of a systematic review of the literature on antibody measures of immunity to coronaviruses , including endemic human coronaviruses ( principally HCoV - 229E , HCoV - HKU1 , HCoV - OC43 , HCoV - NL63 ) , SARS - CoV - 1 , MERS - CoV ( Middle East respiratory syndrome CoV ) and early work on SARS - CoV - 2 . We conceptualize the stages of exposure and infection at which immunity may play a role in the dynamics of SARS - CoV - 2 , and how literature describing work on this and other coronaviruses can provide insights into these stages , as follows . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 5 ( see Figure 1 , a visual abstract of our review ) . First , an exposure to a pathogen generates an immune response that changes over time and between individuals ( antibody kinetics ) . Upon exposure , infection history might play a role in providing protection against new infection , and the literature can provide evidence for such correlates of protection through challenge studies and longitudinal cohort studies . Upon infection , an individualâ€™s immune state , possibly impacted by pre - existing antibodies to other coronaviruses ( among other mechanisms ) , may cause harm through immunopathogenesis , and the literature on this topic primarily consists of in vitro experiments . Correlates of immunity ( or risk through immunopathogenesis ) are complicated by the existence of multiple genera of coronaviruses that are antigenically diverse and may provide cross - protection , and may also cause false positive assay results due to cross - reactivity . Finally , the preceding phenomena at the individual level interact to determine population seroprevalence . Studies that measure these quantities across different age groups can provide evidence , albeit ecological evidence , for or against proposed mechanisms of immunity at the individual level . Methods Search strategy and selection criteria We conducted searches of the PubMed database on March 20 , 2020 using the search term â€œcoronavirusâ€ and each of the following terms or phrases : â€œserolog * â€ , â€œserop * â€ , â€œcross reactivityâ€ , and â€œcomplement fixationâ€ . We also searched for each of these terms with the search terms â€œSARSâ€ and â€œMERSâ€ . Articles were included in the search regardless of publication date . Articles included electronic , ahead - of - print publications available in the PubMed database . We did not attempt to contact authors to obtain unpublished data . Each abstract was reviewed by two reviewers . Articles that were not considered applicable were excluded ( see below ) . Additionally , we identified articles that may be relevant from the reference list of other articles identified by our PubMed searches . Assessment Abstracts were classified as : 1 ) study of antibody immune responses to human coronavirus ; 2 ) study of human coronavirus but not about antibody immunity ; 3 ) study in non - humans or basic biological study of virus - antibody interactions not characterizing actual humans ; 4 ) study in humans not about coronavirus ; 5 ) in another language ; 6 ) duplicate of another record ; or 7 ) dead link / bad return / noise . Disagreement between two reviewers on classification was resolved by a third reviewer . Manuscripts classified in the first category ( study of antibody immune responses to human coronavirus ) were reviewed in their entirety and classified by one reviewer as relevant to one or more of the following : 1 ) antibody kinetics ; 2 ) correlates of protection ; 3 ) antigenic diversity and cross reactivity ; 4 ) immunopathogenesis ; and / or 5 ) population seroprevalence or incidence . Manuscripts that were not considered relevant to any of the preceding categories were excluded . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 6 Data Abstraction Data were digitized from papers according to pre - defined criteria for each area of focus , related to accessibility , utility in answering the key questions and suitability for the pooled analyses ( see Supplementary Appendix for details ) . Data are available at https : / / doi . org / 10 . 5281 / zenodo . 3751566 . Pooled Analyses We conducted pooled analyses in two areas where data were available and sufficiently comparable to include in a single analysis . Antibody kinetics and association of antibody responses with clinical severity We summarized approximate time to detection across studies for two sets of studies . The first set includes studies with cumulative number of positive cases over time . Each additional positive case added to the cumulative curve was assumed to be a new detected case at that time point . This is approximate only , because cumulative curves sometimes decline ( Figure S1 ) , indicating some participants were lost to follow - up . Second , we identified data that described either seropositivity as a function of time , or measures of antibodies with a reported cutoff . Data was included if ( i ) the first seropositive time point was within three weeks of illness onset or ( ii ) the first estimate ( s ) were negative , but a subsequent measurement within three weeks of the first was positive . Population seroprevalence We estimated the annual force of infection from age - stratified seroprevalence data , assuming that individuals acquire infection with a single , strain - specific force of infection that is constant in time using standard methods 18 , and that once an individual becomes seropositive they remain seropositive for the remainder of their lifetime ( regardless of their protective status ) . We estimated the total force of infection ( FOI ) from the four major endemic strains by drawing 100 , 000 bootstrap samples of four strain - specific FOIs and calculating the sum across strains . Age at first infection is given by the inverse of total FOI . Results Manuscript identification Our searches identified 1281 abstracts of potential relevance ( Figure 2 ) . Two reviewers read each abstract and identified 322 manuscripts for full review . Manuscripts were classified into our areas of focus . Below , we present the findings of our review for each area of focus . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 7 General background for multiple areas of focus : Serological assays Multiple serological assays have been used to characterize antibody responses to coronaviruses . Assays we encountered in our review fell into two major categories ( Table S1 ) . The most commonly used assays were binding assays , including enzyme linked immunosorbent assays ( ELISA ) , immunofluorescence assays ( IFA ) , Western blots , hemagglutination inhibition ( HAI ) , and complement fixation ( CF ) . The second category of assays was neutralization assays . Neutralization assays are typically considered the gold standard for measuring functional antibody responses as they measure biological activity throughout the viral replication process . Researchers have used assays of both types to characterize antibody activity by antibody class ( i . e . IgG , IgM , IgA ) . As these antibodies are known to have different temporal dynamics , we reported when specific classes of antibodies were characterized in figures . If no characterization was specified , we reported the measures of antibody aggregated across all classes . The source of samples in the reviewed studies was almost exclusively serum samples . However , mucosal samples collected by swab or nasal washings were also reported . Antibody kinetics and association of antibody responses with clinical severity Initially , 56 studies were classified as relevant to antibody kinetics , and 40 as relevant to the association of antibody responses with clinical severity . Of these , 27 were selected after further review ( 4 on endemic HCoV , 10 on MERS - CoV , 11 on SARS - CoV - 1 , and 3 , including 2 non - peer - reviewed preprints , on SARS - CoV - 2 ) . Table S2 provides summaries of these studies . We digitized data from a subset of 22 studies that included sufficient detail on longitudinal antibody measurements ( Supplementary Data File S1 ) . 18 % of studies reported cumulative seroconversion only . 73 % of the digitized studies provided estimates during the first week after onset of symptoms , while 77 % had measurements at least one month after onset of symptoms . Antibody kinetics post infection In the studies we shortlisted , antibody responses to infecting coronaviruses were rarely reported during the acute phase of illness ( 1 - 7 days ) 19 â€“ 22 . Many studies reported an immune response , characterized by a robust increment of antibody titers for HCoV - 229E , MERS - CoV , SARS - CoV - 1 , and SARS - CoV - 2 after the second or third weeks following the onset of illness 8 , 23 â€“ 30 . Callow et al . 8 found similar dynamics in IgA and IgG across 10 individuals experimentally infected with HCoV - 229E : antibody levels increased after 8 days and peaked around 14 days , although significant variation between patients was reported . Yang et al . 31 , analyzing data across 67 patients , found higher positive rates of IgM against SARS - CoV - 1 than IgG during the first month . They further found that the proportion of patients who seroconverted for IgM peaked 30 days after onset , followed by a gradual decrease of IgM levels , while IgG levels peaked by week 25 31 . Another study on 30 SARS - CoV - 1 infected patients 32 detected seroconversion of IgG , IgM , and IgA at similar times , indicating that the earliest they reached a peak was on average 15 days . While it is currently too early to characterize how anti - SARS - CoV - 2 antibodies will change over prolonged periods of time , preliminary studies have analyzed antibody changes in recent . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 8 infections . Tan et al . 33 found that IgM was detected on day 7 and peaked on day 28 ( across 28 patients ) , and IgG appeared by day 10 and peaked on day 49 ( 45 patients ) , while Zhao et al . 34 determined that seroconversion among 173 patients took place at median times of 12 ( IgM ) , 14 ( IgG ) , and 11 ( neutralizing antibodies ) days . Multiple studies reported that while IgM and IgG titers increased during the first weeks following symptom onset , IgM levels gradually waned ( while remaining detectable ) for SARS - CoV - 1 and MERS - CoV in comparison to IgG levels about a month post follow - up 23 , 32 . Most studies that examined antibody kinetics over extended periods of time focused on IgG 32 , 35 â€“ 40 . Callow et al . 8 found among experimental infections with HCoV - 229E that after peaks in IgG and IgA , antibody levels waned and between 11 weeks and 1 year post inoculation were at similar levels to those found in inoculated but uninfected patients . Other studies 35 , 40 reported detectable IgG levels in recovered MERS - CoV patients , respectively at five months and one year after illness onset , while another 31 detected IgG antibodies across 67 SARS - CoV - 1 patients after 82 weeks , the endpoint of the study . We found few studies that analyzed changes in antibody kinetics over the course of many years after illness onset 36 , 37 . Cao et al . 37 described similar long - term dynamics in IgG and neutralizing antibodies over the course of a 3 - year study on SARS - CoV - 1 : titers for both peaked at month 4 , and while they waned thereafter , 74 . 2 % and 83 . 9 % of patients had detectable levels of IgG and neutralizing antibodies , respectively , at month 36 . Correlation between severe disease and rise in post - infection antibody level Studies have increasingly explored a potential link between case severity and antibody response ; however , the available information analyzing the nature of this relationship is uneven across viruses . Several studies on MERS - CoV as well as the first preliminary analyses on SARS - CoV - 2 explicitly explore this connection , while fewer studies on endemic HCoVs and SARS CoV - 1 do so . Several studies found that cases of varying severity ( e . g . , asymptomatic , mild , and severe ) developed detectable antibodies against HCoV - 229E , SARS - CoV - 1 , SARS - CoV - 2 , and MERS - CoV 33 , 41 â€“ 44 . One study 45 found that the rise in antibodies between acute and convalescent sera correlated positively with symptoms and clinical score in 15 patients experimentally infected with HCoV - 229E ( Table 1 ) . However , most studies of SARS - CoV - 1 did not report symptom severity , and evidence of differences in antibody responses among cases experiencing symptoms of different severity is inconclusive . SARS - CoV - 1 survivors with sequelae were found to have lower neutralizing antibodies than patients without sequelae 37 , although the same study otherwise found no significant differences in kinetics according to disease severity . Another study 39 found no evidence of difference in antibody responses between patients who survived or died . In MERS - CoV , on the other hand , Ko et al . 46 found that both seroconversion rate and peak antibody levels increased with disease severity , while Okba et al . 47 reported a robust response to severe infections as opposed to low or no seroconversion in asymptomatic and mild cases . Milder infections also appeared to be less likely to elicit serologic responses 47 , 48 , although Okba et al . suggests that seroconversion detection may depend on the antibodies being targeted . More severe cases were also found to have slower responses 24 , 27 ; 75 % of patients who died had not seroconverted by week 3 46 . Some authors have hypothesized 47 , 49 that seroconversion rates in severe cases may be associated with prolonged viral shedding , and that low antibody responses . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 9 in mild cases may be due to short - lived infections . Another study 40 suggested that weaker antibody responses to endemic HCoVs ( specifically HCoV - 229E ) might be because these mainly infect the upper respiratory tract . Preliminary studies on SARS - CoV - 2 point to a possibly contrasting pattern to MERS - CoV : while IgM antibodies appear at the same time in severe and non - severe cases , IgG appears sooner in severe cases 33 . On the other hand , neutralizing antibody titers were higher in severe cases 34 . The distributions of time points at which antibodies were detected ( see Methods ) in the digitized data are shown in Figure 3 . The median time to detection was similar across different antibodies for SARS - CoV - 1 ( 12 days ; IQR 8 - 15 . 2 days ) and SARS - CoV - 2 ( 11 days ; IQR 7 . 25 - 14 days ) , but longer for MERS - CoV ( 16 days ; IQR 13 - 19 days ) . Severity appears to be associated with time to detection of IgM in MERS - CoV cases only ( 2 days longer ) , and IgG in both MERS - CoV and SARS - CoV - 2 ( 2 to 3 days longer for more severe cases ) . All data on time to seroconversion was based on symptomatic patients . No data were available for asymptomatic individuals . Figure 4 provides a broad sense for trajectories of antibodies ( also see Figures S2 and S3 ) . Most longer - term studies ( > 10 weeks ) were for MERS - CoV and reported IgG and neutralizing antibodies ; these showed the presence of IgG and neutralizing antibodies up to 60 weeks after symptom onset ( Figure 4 ) . The studies reporting symptom severity with longer - term data focused on MERS - CoV . Not all of these studies reported a cutoff for the assay used ; in those that did , two thirds of patients with mild symptoms had detectable or positive IgG antibodies at six months and one year , while all patients with severe symptoms had detectable IgG antibodies at the same points in time ( Table 1 ) . Correlates of protection Identification of a correlate of protection requires characterization of immune responses prior to a known exposure or period of risk in which infection or illness outcomes are characterized . In our review , we found that this level of detail was only present in human challenge experiments with HCoVs . We identified 18 studies in which volunteers were exposed to experimental infections with HCoV . Of these , 6 associated pre - infection antibody measurements with either virologic , serologic or illness outcomes upon experimental infection ( Table S4 ) . The earliest identified experimental infection study of coronaviruses found that 7 of 8 with neutralizing titer < 5 excreted virus after experimental exposure compared to only 1 of 4 with pre - exposure titer of 40 or greater 10 . Interestingly , this study is one of the few to report illness as a function of dose of viral inoculum given in the challenge experiment and suggests that those given higher doses ( > 10 1 . 2 TCD50 ) were more likely to experience colds ( 10 / 15 ) than those exposed to lower doses ( < 10 0 . 7 TCD50 ) ( 3 / 11 ) . Barrow et al . 50 found lower proportions of individuals with high neutralizing titer experienced â€˜significant coldsâ€™ upon viral challenge than individuals with low titer . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 10 Callow 12 characterized IgA , IgG and neutralizing antibody in sera and nasal washings from 33 volunteers before they were experimentally exposed to 229E HCoV . She found that multiple antibody responses were associated with reduced risk of infection , seroconversion , and symptomatic illness upon challenge . Individuals who seroconverted to the experimental viral exposure ( defined as a rise in ELISA IgG serum antibodies ) had significantly higher serum IgG , neutralizing antibodies , and nasal IgA . Serum and mucosal IgA were associated with the duration of viral shedding post experimental infection , with those shedding for 5 days or more having statistically significantly less mucosal IgA than those shedding less than 5 days ( 0 . 6 ng / ml versus 4 . 7 ng / ml , p < 0 . 01 ) . Serum neutralizing antibody was not found to be significantly associated with viral shedding duration . This study also showed protective associations of pre - infection serum neutralizing antibody , serum IgG and nasal IgA with clinical severity scores and nasal secretion weights ( a measure of severity of rhinorrhea symptoms ) . Another prospective study 51 reported detection of pre - existing neutralizing antibodies among medical students who had virus isolation ( 67 % , n = 8 / 12 ) or seroconversion to HCoV - 229E ( 25 % , n = 3 / 12 ) . Pre - existing neutralizing antibodies were inversely associated with increases in neutralizing antibodies after re - infection , but were not associated with reinfection events that were determined by CF seroconversion . Experimental re - infection or re - challenge Several studies exposed volunteers to two challenges of virus , some months apart . Reed re - challenged 6 volunteers who had been experimentally infected 8 - 12 months previously 9 . On the first challenge , all 6 developed symptoms and detectable viruses and 5 of 6 experienced significant rise in titer . In the second , 0 / 6 experienced illness , detectable virus or significant rise in titer . Callow et al re - challenged volunteers with the same dose of coronavirus , one year apart 8 . Of 9 volunteers who were infected in the first exposure , 6 ( 67 % ) were infected in the second exposure . However , none of these individuals developed respiratory illness symptoms and they experienced a mean duration of detectable virus of 2 days compared to a mean of 5 . 6 in the initial challenge . Cross - reactivity and antigenic diversity We identified 73 papers as related to cross - reactivity and / or antigenic diversity ( Table S5 ) . Of these studies , 43 were identified as highly important and were described in the text , and data was digitized from 7 studies ( Supplementary Data File S2 ) . General background for this area of focus : Genetic relationships of human coronaviruses and immunogenic proteins Within the Coronaviridae family , the Coronavirinae subfamily includes four distinct genera . The Alphacoronaviruses include two major human coronaviruses , HCoV - 229E and HCoV - NL63 . Multiple HCoV - 229E - like strains have also been characterized . The Betacoronaviruses are categorized into 4 lineages . Lineage A includes HCoV - OC43 and HCoV - HKU1 , Lineage B . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 11 includes SARS - CoV - 1 and SARS - CoV - 2 , Lineage C includes MERS - CoV and multiple bat coronaviruses , and lineage D contains coronaviruses thus far only identified in bats . HCoV - OC43 and HCoV - 229E are documented to cause common cold while the more recent strains ( HCoV - HKU1 and HCoV - NL63 ) infect both the upper and lower respiratory tract , resulting in more severe but rarely fatal disease 52 . Other CoVs have been associated with human disease , including enteric disease in infants and zoonotic infections from livestock , but seem rare and are not described here 9 , 53 â€“ 58 . Coronaviruses have four structural proteins : the spike protein ( S ) , the nucleocapsid ( N ) , the envelope protein ( E ) and the membrane protein ( M ) 59 , 60 . The S protein , which protrudes from the virus envelope , is immunodominant and consists of two subunits : the S1 protein , which contains the receptor binding domain ( RBD ) and the S2 protein , which mediates cell membrane fusion 61 , 62 . The nucleocapsid protein , which is also immunogenic , is smaller than S , lacks a glycosylation site , and induces antibodies sooner than to S during infection , making it an attractive protein for diagnostic assay design 63 . Sequence homology for the N and S of SARS - CoV - 1 to other Betacoronaviruses is 33 - 47 % and 29 % , respectively , while homology to Alphacoronaviruses is lower ( 25 - 29 % homology to N and 23 - 25 % for S ) 63 . SARS - CoV - 2 is most similar to SARS - CoV - 1 , harboring sequence homology of 90 % in N and 76 % in S followed by MERS - CoV ( 48 % and 35 % , respectively ) 64 . Natural and experimental infection studies in humans point to cross - reactivity within but minimal reactivity between endemic human Alpha - and Betacoronaviruses . Individuals experimentally inoculated with HCoV - 229E and HCoV - 229E - like strain LP experienced a > 4 - fold rise in neutralizing antibodies to both HCoV - 229E and LP , while individuals inoculated with HCoV - OC43 did not 65 . However , while volunteers experimentally inoculated with HCoV - 229E - like strains were protected against challenge with the homologous strain at one year ( n = 6 / 6 ; none shed virus , showed symptoms , or had a rise in antibodies ) , volunteers experienced only partial protection against heterologous HCoV - 229E - like strains ( n = 5 / 12 protected ) . Increasing population immunity to HCoV - 229E in the population was associated with less clinical disease upon challenge with HCoV - 229E - like strains 9 . Studies of serological responses to HCoV N proteins point to cross - reactivity within Alpha - HCoVs ( 229E and NL63 ) and Beta - HCoVs ( OC43 and HKU1 ) but not between Alpha - and Beta - HCoVs 66 â€“ 68 . Consistent with observations in human challenge studies , children experiencing natural HCoV infections experience 4 - fold seroconversions to either HCoV - OC43 or HCoV - 229E but not both simultaneously 69 . However , a longitudinal study in newborns found that children seroconverted to either HCoV - NL63 or HCoV - 229E but not both , although both viruses are Alpha - HCoVs 70 . A later study in newborns followed from age 0 to 20 months 71 showed asymmetric interactions within Alpha - HCoVs and Beta - HCoVs : seroconversion to HCoV - NL63 was observed after HCoV - 229E but no recent HCoV - 229E seroconversions had a recent infection by HCoV - NL63 , suggesting HCoV - NL63 provides at least short - term protective immunity against HCoV - 229E . Similarly , HCoV - HKU1 seroconversion occurred prior to HCoV - OC43 but rarely after , suggesting HCoV - OC43 protected against HCoV - HKU1 . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 12 Infection with endemic HCoVs produces little cross - reactivity to emerging CoVs SARS - CoV - 1 and MERS - CoV . Individuals experiencing natural infections with HCoV - OC43 or HCoV - 229E did not have detectable antibodies in acute or convalescent samples against SARS - CoV - 1 ( to N protein 72 ; by IFA or neutralization 39 ) . Healthy individuals with antibodies to HCoV - 229E , HCoV - OC43 , and other endemic HCoVs rarely had detectable antibodies that bound SARS - CoV - 1 infected cells or SARS - CoV - 1 N protein 68 , 73 , 74 . HCoV - OC43 N and SARS - CoV - 1 N proteins have a subset of sites with shared homology , potentially explaining low - level false positive results for N - based assays 75 . Blood donors in Southern China ( n = 152 ) and Saudi Arabia ( n = 130 ) did not have detectable binding ( IFA ) or neutralizing antibodies to either MERS - CoV or SARS - CoV - 1 76 , 77 . Because children experience less severe disease during SARS - CoV - 1 infection than adults , it was hypothesized that childhood vaccination with non - CoVs provided cross - protection against SARS - CoV - 1 . However , binding and neutralizing antibodies and T cell responses induced by routine childhood vaccinations ( AMPV , BCG , DPT , HBV , HIB , JEV , MMRV [ and MV , RV ] , OPV , PI , SV , VV [ varicella vaccine ] ) did not cross - react with SARS - CoV - 1 in experimentally inoculated mice 78 . Emerging HCoVs can induce cross - reactive binding antibodies toward endemic and other emerging HCoVs SARS patients often experience a > 4 - fold rise in antibody to HCoV - 229E , HCoV - NL63 , and / or HCoV - OC43 in paired acute / convalescent samples ( n = 12 / 20 ) 39 . In one study , the number of SARS patients who experienced a > 4 - fold rise in binding antibodies was greater to HCoV - OC43 ( n = 10 / 11 ) than HCoV - 229E ( n = 5 / 11 ) 73 . Some SARS patients also showed a rise in antibodies to HCoV - 229E and HCoV - OC43 N protein 73 and HCoV - NL63 79 . Among SARS - CoV - 1 patients ( n = 28 ) , 60 % had detectable IFA titers to MERS - CoV and 25 % had anti - MERS - CoV neutralizing antibodies . A subset with available paired samples experienced seroconversion to HCoV - OC43 , but limited seroconversion to Alpha - CoVs . In the same study , animal handlers at a wildlife market in Guangzhou ( n = 94 ) with low - level prevalence of antibodies to SARS - CoV - 1 ( 13 . 8 % by IFA , 4 . 3 % by NT ) had detectable antibodies toward MERS - CoV ( 2 . 2 % by IF ) 76 . A follow - up study found that the cross - reactivity between SARS - CoV - 1 and MERS - CoV was unlikely to be due to similarity in the receptor - binding domain ( RBD ) , as monoclonal antibodies ( mAbs ) raised to SARS - CoV - 1 RBD did not bind MERS - CoV RBD or neutralize MERS - CoV even at high concentrations 80 . MERS - CoV may produce less cross - reactivity against SARS - CoV - 1 . A subset of slaughterhouse workers in Saudi Arabia had antibodies to MERS - CoV by IFA as well as to pandemic HCoVs , but none had reactivity to SARS - CoV - 1 spike protein . MERS - CoV patients were observed to have low - level cross - reactivity to SARS - CoV - 1 77 and in one study HCoV - HKU1 N protein 79 . Because of this cross - reactivity , researchers have developed diagnostic assays with truncated SARS - CoV - 1 S , N , and M proteins 81 â€“ 84 . See Figure 5 for associations between homologous and heterologous titers . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 13 There is some evidence for antigenic evolution in the receptor binding domain of emerging CoVs A study of SARS - CoV - 1 strains from the zoonotic phase ( palm civets and bats ) to early and late in the SARS epidemic revealed that some escaped neutralization by mAbs targeting the spike RBD of SARS - CoV - 1 85 â€“ 87 . Sera from BALB / c mice immunized with full length S protein from civet strains were ineffective against human SARS - CoV - 1 and vice versa 88 . Despite significant cross - reactions between mAbs against conformational epitopes of RBD with multiple mutational differences , single mutations were shown to disrupt neutralizability 89 . In contrast , mAbs targeting regions critical for fusion and entry on the S2 protein are immunogenic and can broadly neutralize SARS - CoV - 1 strains 59 , 90 . A recent study showed reduced binding of mAbs from SARS patients to the RBD of SARS - CoV - 2 , especially those that blocked binding to the ACE2 receptor . The only mAb potently bound to SARS - CoV - 2 RBD protein did not compete with the RBD for binding to the ACE2 receptor , suggesting it bound a different , conserved site on the protein 91 . Similar studies were conducted to study changes in MERS - CoV . Five recombinant RBD proteins were constructed with mutations detected from MERS - CoV strains isolated in humans ( 2012 - 2015 ) and camels 92 . These RBDs maintained functionality and induced potent neutralizing antibodies . When residues in their receptor binding motifs were mutated to evade neutralization , cross - reactivity persisted but binding affinity to DPP - 4 ( the main receptor for MERS - CoV ) was lost , suggesting limited antigenic escape for MERS - CoV . A study of MERS - CoV isolates with distinct amino acid differences in the S and other replication proteins found differences in replication kinetics , but it is not clear that these were attributable to differences in S 93 . Immunopathogenesis In the initial review , 38 papers were identified as related to immunopathogenesis . Of these , we found 25 sufficiently relevant to review in Table S6 , and 16 of those are detailed below and summarized in Figure 6 . Antibody - dependent enhancement ( ADE ) may be possible Multiple studies have suggested the possibility that pre - existing antibodies increase disease by facilitating viral entry into cells . This mechanism , a long hypothesized explanation for severe dengue infections , is called antibody - dependent enhancement ( ADE ) . This has also been hypothesized as relevant to coronaviruses specifically in patients who seroconverted early in SARS - CoV - 1 infection 25 , 94 , 95 . Reasons why some individuals can mount responses more quickly than others are unknown , but the correlation between greater age and early response with higher titers suggest priming effects from existing antibodies against endemic strains 95 . Authors from another study pointed toward enhancement from antibodies within the episode 17 . Nasopharyngeal viral load increased in the first week and declined thereafter but clinical worsening was seen in many of the patients at week two , with virus shedding in stool and urine observed towards the end 25 , 94 . Many manifested with new - appearing lesions as original lesions improved . The timing of the appearance of new lesions correlated with IgG seroconversion , suggesting that pathology post week one was driven by the immune response rather than by uncontrolled viral replication . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 14 Others have argued that ADE due to neutralizing antibodies is unlikely as treatment of SARS - CoV - 1 with convalescent serum did not result in adverse effects 95 . Observation of increased risk of disease in infants with mid - levels of maternal antibody to dengue ( compared to high or low levels of maternal antibody ) is important evidence supporting the role of antibody in pathogenesis for dengue 96 . A similar mechanism has been identified for seropositive and seronegative kittens infected with feline infectious peritonitis virus , a coronavirus that causes fatal disease in cats 97 . One study characterizing endemic HCoV in infants observed the highest lower respiratory tract infection burden ( 7 . 8 % ) at 6 - 23 months of age ( 1 . 5 % at < 6 months , close to none at 2 - 5 years ) while upper respiratory tract infection burden was close to uniform 98 . The heightened disease burden after maternal immunity waning to medium levels in the lower tract , and the absence of such observation in the upper tract where antibodies do not circulate , subtly supports the possibility of ADE in HCoVs . Suggestive enhancement mechanisms from in vitro experiments Controlled in vitro experiments have explored the possible enhancing action of antibodies for HCoV infections . A series of studies by Yip et al . demonstrated that opsonization of anti - spike antibodies allowed SARS - CoV - 1 to enter non - ACE2 expressing immune cells that bear Fc - ð›¾ - RII ( CD32 ) 99 , 100 . Though replication is observed after entry , the virus does not exit nor alter the expression of proinflammatory immune mediators ( CCL2 / MCP - 1 , CCL3 / MIP - 1 ð›¼ , CXCL10 / IP - 10 , TNF - ð›¼ ) and apoptosis inducing ligands ( FasL ) 101 . This contrasts with effects in nonhuman primate studies where endocytosis into macrophages stimulated inflammation , which in turn drove severe lung injuries 102 . A study by another group in human promonocyte cell line ( HL - CZ ) , which expresses both ACE2 and Fc - ð›¾ - RII , demonstrated increased infectivity and virus - induced apoptosis when anti - SARS - CoV - 1 sera from patients were added at 100 - to 2000 - fold dilutions , while at higher concentrations neutralization occurred 103 . Upon infection , TNF - ð›¼ , IL - 4 and IL - 6 expressions heightened , while IL - 3 and IL - 1 ð›½ only appeared in trace amounts . The difference could have resulted from the cell line differences or the set of mediators assessed 104 . Regarding regions of the spike protein that may induce antibodies with enhancement effects , both anti - S1a and anti - S1b mAbs showed mild to moderate effects 103 . Only one particular anti - S1b clone showed neutralization . No effect was seen for anti - N mAbs . There is limited evidence that these mechanisms are causal to inflammatory gene expression differences among patients with differing severities 105 . Direct damage caused by antibodies While the link between antibody presence and enhanced severity via infection of immune cells remains unclear , some have suspected a role for auto - reactive responses in increased severity of illness . Prolonged tissue destruction can increase presentation of host proteins to T - or B - cells and result in an adaptive response against self , i . e . epitope spreading 52 . Anti - S2 IgG antibodies targeting uninfected lung epithelial cells ( A549 ) were detected in SARS - CoV - 1 patients after twenty days post - symptom onset 106 , a reactivity not seen in serum from healthy individuals and non - SARS - CoV - 1 pneumonia patients . Complement inactivation only showed cytotoxic effect . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 15 when IgG was present / unbounded . Presence of anti - S2 antibodies also increased the binding of immune cells ( PBMCs ) to A549 cells treated with IFN - ð›¾ , replicating the conditions under which a cytokine storm would be observed . A separate study demonstrated colocalization of anti - S2 Abs collected from serum of SARS patients â‰¥50 days post - fever onset with annexin A2 and immunoprecipitated annexin A2 on A549 cell surfaces . Elevated expression of annexin A2 on the surface can be stimulated by IL - 6 and IFN - ð›¾ , both cytokines induced by SARS - CoV - 1 , which in turn increases binding of anti - S2 Abs to the cell . However , its pathogenic role was not explored 107 . Alternatively , similarity between viral and host epitopes ( molecular mimicry ) can generate cross - reactive antibodies . In mice 108 and humans 109 , there is evidence of anti - N antibodies that cross react with IL - 11 , an anti - inflammatory cytokine expressed in many tissues , including lung and bone marrow . The authors suggest high anti - N antibodies induced relatively early during infection may be involved in the thrombocytopenia and lymphopenia observed early in SARS - CoV - 1 infection 108 . Population seroprevalence From the paper review , 68 papers were classified as having data on age and seroprevalence or seroincidence , of which 20 studies were confirmed on further review , and 14 had digitizable data . The age range across studies was 0 to â‰¥65 , while the sample size of studies ranged from 69 - 19 , 974 ( 82 - 6 , 400 for studies of endemic HCoVs ) . Table S7 and Supplementary Data File S3 contain details of the studies . Seroprevalence to endemic coronaviruses increases rapidly during childhood For endemic coronaviruses , seroprevalence rises sharply in childhood , with little to no change in seroprevalence by age among adults . While exact dynamics from 6 months to 20 years vary between studies , the general trend remains consistent . Figure 7 displays HCoV age - seroprevalence curves for the 7 papers with digitizable data on seroprevalence by age , with the panels representing the four major endemic strains 74 , 110 â€“ 115 . Trends from papers not displayed in the figure are largely the same 68 , 70 , 116 , 117 . Two studies show a marked decline in seroprevalence with age above 40 68 , 111 . Seroincidence of endemic coronaviruses occurs in all age groups , with no clear trend Available data sets are more sparse for incidence , and the patterns are inconsistent between studies 110 , 118 â€“ 120 . Figure 8 displays age - incidence curves for the 4 papers with digitizable data on incidence by age , with each panel representing the two strains included in these studies ( HCoV - 229E and HCoV - OC43 ) . There was an increasing trend in seroincidence with age during an outbreak for HCoV - 229E in Tecumseh , Michigan 110 , but a similar analysis of HCoV - OC43 seroincidence in the same outbreak showed no such increase 118 . Longitudinal follow - up of 10 . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 16 families in Seattle found a lower rate of seroconversions among adults compared to children 119 . A comparison of a cohort of 21 - 40 year - olds and a cohort of â‰¥65 year - olds found no clear difference in incidence between the two age groups , as measured by seroconversion or PCR - confirmed , HCoV - associated respiratory illness 120 . Finally , observational studies have shown evidence of coronavirus - associated respiratory illnesses in elderly populations 121 â€“ 123 and across all ages 124 . The force of infection of endemic coronavirus strains is high , and the age at first infection low , but variable across studies . Simple catalytic models fit to the digitized data predict median total force of infection across studies of 0 . 21 ( 95 % CI 0 . 09 , 0 . 40 ) ( see Table S8 for estimates by study ) , corresponding to an average age at first infection with any strain of 4 . 8 years ( 95 % CI 2 . 5 , 11 . 2 ) . A cohort of 25 infants followed from birth for an average of two years experienced annual strain - specific incidence rates from 0 . 12 - 0 . 70 70 , 71 . Zhou et al . â€™s serosurvey measured IgG and IgM separately , and showed very different patterns with age 115 ( Figure 7 ) . While IgG seroprevalence rose to high levels by age 10 and remained high into the adult population , IgM seroprevalence declined to zero for all individuals aged 14 and older . The authors interpreted this as evidence that first infections occurred before the age of 14 for all strains . Data are incompatible with complete , lifelong homologous immunity to endemic coronaviruses The rapid rise in seroprevalence with age observed in the literature suggests a force of infection ( and thus proportion seropositive to all serotypes at older ages ) high enough to preclude significant rates of coronavirus infection among older adults if each serotype confers lifelong homologous immunity ( Figure 9 , green dotted line ) . On the other hand , short - term , complete immunity , lifelong partial immunity , and the existence of multiple genotypes within a single serotype with limited cross - immunity could explain the age - seroprevalence and age - incidence curves seen in the literature ( Figure 9 ) . Further observations from review The review gave rise to several observations that were either consistent or conflicting across papers . Studies that enrolled children less than 6 months detected loss of maternal antibodies , representing a preliminary line of defense for newborn children 70 , 71 , 74 , 117 . Most studies showed no discernible difference in age - seroprevalence trends or in overall seroprevalence by strain . Gao et al . 68 found that seroprevalence of HCoV - 229E and HCoV - HKU1 was significantly lower than seroprevalence of HCoV - OC43 and HCoV - NL63 . In addition , Chan et al . 114 found seroprevalence to HCoV - HKU1 to be low ( 21 . 6 % in 31 - 40 year olds ) in Hong Kong , and stated that this was expected from the low rates of HCoV - HKU1 among respiratory illnesses . Finally , most studies measured the presence of binding antibodies in the blood . Of the studies in Figure 7 , only Cavallaro and Monto 110 ( red ) measured seropositivity using a neutralization assay . That the seroprevalence is markedly lower in that study compared to the others could indicate lower test . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 17 sensitivity compared to more modern tests , or of the lack of correlation between neutralizing and binding antibodies against endemic coronaviruses . Regarding the novel coronaviruses , serosurveys of SARS - CoV - 1 confirmed that the rate of asymptomatic or subclinical infection was very low 125 . Asymptomatic and subclinical rates of MERS - CoV are generally higher , but available serosurveys lack the power to draw strong inference about age trends . A large serosurvey conducted across Saudi Arabia found that the age of seropositive individuals was significantly lower than the age of clinical cases 126 , while another conducted across multiple countries in Africa and Asia found no trend in seroprevalence with age 127 . Studies of risk factors within camel workers have either not addressed age as a risk factor 128 , 129 or not found an association 130 . Discussion Key findings We have presented a broad , comprehensive review of multiple aspects of the literature on antibody immunity to coronaviruses . We identified a number of key findings . The median time to detection was similar across different antibodies for SARS - CoV - 1 ( 12 days ; IQR 8 - 15 . 2 days ) and SARS - CoV - 2 ( 11 days ; IQR 7 . 25 - 14 days ) , but longer for MERS - CoV ( 16 days ; IQR 13 - 19 days ) . Most long - term studies found that IgG waned over time ( typically detectable up to at least a year ) while others found detectable levels of IgG three years post symptoms onset . Antibody kinetics varied across the severity gradient with longer durations of detectable antibody associated with more severe symptoms . Human challenge studies with HCoV indicate that serum and mucosal immune responses ( serum IgG , IgA , neutralizing titer , mucosal IgA ) provide possible correlates of protection from infection and disease . However , repeat human challenge experiments with single HCoV suggest individuals can be infected with the same HCoV one year after first challenge , but with possible lower severity . There is cross - reactivity within but minimal reactivity between Alpha - and Beta - CoVs . While endemic HCoVs rarely induce cross - reactive antibodies against emerging HCoVs , SARS - CoV - 1 and MERS - CoV stimulate antibodies induced by prior HCoV infections . Multiple mechanisms for immunopathology have been suggested but no strong causal evidence exists and the extent to which the presence of antibodies affects human disease severity is not known . Seroprevalence with the four major endemic HCoV strains rose rapidly during childhood and remained high in adults . The median age at first infection with any strain was 4 . 8 years ( 95 % CI 2 . 5 , 11 . 2 ) . There was no clear trend in seroincidence with age , and many studies have demonstrated incidence of coronavirus infections in elderly populations . These results suggest a measurable impact of immunity to coronaviruses on future risk , but this protection may be transient . Limitations of systematic review We have suggested a set of search terms to identify relevant work , and others may expand on this search . Due to the speed of new research being produced , we limited our systematic review . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 18 of SARS - CoV - 2 papers to before March 20 , 2020 . Further evidence on immune responses to SARS - CoV - 2 is likely contained in work that has since been published . We excluded from the review animal studies and studies of animal CoVs to remain human - focused , but this literature is likely relevant to some areas of the review . We limited the scope of the review to antibody - mediated immunity , meaning that understanding of some areas of the review may be incomplete . Finally , digitized data could be affected by publication bias or other selection bias , meaning that it might not be representative of data from all studies . The aim of the pooled analyses was to summarize the array of studies rather than formally explore hypotheses , and as a result the models used are simple . For example , in estimating force of infection from age - stratified seroprevalence data , we did not consider other features of a model such as assay sensitivity , time - and age - varying force of infections , seroreversion , and cross - reactivity between strains , that might better explain patterns seen in the data . Implications for SARS - CoV - 2 pandemic responses and future outlooks Serological assay development There is a need for development of serological assays with high sensitivity for screening and sufficient specificity to exclude individuals from unneeded interventions . Evidence from previous emerging CoVs suggests that false negativity is likely to result from waning of antibody levels . As most studies on antibody kinetics are on symptomatic patients , the kinetics in subclinical infections , a significant proportion of SARS - CoV - 2 infections 131 , remains a key gap in the literature . Indications that less severe illnesses are associated with reduced antibody responses suggests that mild cases may pose challenges to serological assays . On the other end , the proposed policy of â€œimmunity passportsâ€ to allow individuals presumed immune to return to work once social distancing measures are relaxed requires highly specific serological tests to mitigate adverse outcomes . Evidence from past emerging HCoVs suggests low false positivity from cross - reaction with endemic HCoVs . However , antibody titers do not necessarily translate to immunity . Challenge studies indicate multiple candidates that may serve as correlates of protection including serum and mucosal measures ; however , these will need specific evaluation for SARS - CoV - 2 . The knowledge gap in correlates of protection and their durability must be filled before immunity passports are safe for general use . Therapeutics , vaccines , and ADE Pharmaceutical interventions to protect susceptible individuals or improve outcomes among sick individuals will first need to be tested in randomized trials . Vaccines with various antigens are currently under development 132 and polyclonal antibodies from SARS - CoV - 2 - recovered patients have been used in some cases for treatment 133 . Though the evidence for immunopathogenesis remains limited 134 , it will be important to design rigorous trials that can provide valid evidence of positive effect but also detect negative effects if they occur with associated adaptive stopping criteria . Such concerns might extend beyond vaccine development if negative effects are subtle and not or weakly detectable in Phase III studies . In the event of mass vaccination following . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 19 successful efficacy studies , surveillance designed to detect waning immunity and adverse events due to vaccine - mediated immunopathogenesis is critical . Long - term dynamics of SARS - CoV - 2 and concluding remarks Key questions for the long - term dynamics of SARS - CoV - 2 include whether it is likely to be eradicated , whether widespread immunity will lead to transient decreases in incidence and how long it will take for another large outbreak to occur . Modeling studies will be crucial in answering these questions , but they will rely on an understanding of immune responses to SARS - CoV - 2 and interactions with other coronaviruses to make relevant predictions . Analysis of datasets , specifically of serosurveys , needs to account for the kinetics of waning immunity and effects of imperfect assays to draw meaningful inferences . Finally , we note that the best evidence for immune responses to SARS - CoV - 2 will come from studies of the virus itself . Such studies are being performed and reported with unprecedented speed , but in the absence of firm evidence many are turning to the existing coronaviruses as a model . To that end we have produced this review to aid researchers in understanding the scope of the evidence for immune responses to these coronaviruses . Acknowledgements This research was supported [ in part ] by the Intramural Research Program of the National Human Genome Research Institute , National Institutes of Health . DATC was supported by the US National Institutes of Health award number R01 - AI114703 - 01 . APW is funded by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and by the National Library of Medicine of the National Institutes of Health under award number DP2LM013102 . IRB was supported by the John A Watson Faculty Scholar fellowship . We thank Celeste Dale and Maxwell Hogshead for assistance in data digitization . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 20 Main Text Figure Titles Figure 1 : Aspects of antibody response included in this review . Figure 2 : PRISMA Diagram of Systematic Review . Figure 3 : Distributions of times from symptom onset to detection of antibodies against MERS , SARS - CoV - 1 and SARS - CoV - 2 . Figure 4 : MERS - CoV antibody kinetics . Figure 5 : Antigenic and phylogenetic relationships among HCoVs . Figure 6 : A diagrammatic summary of evidence supporting ( red ) and contradicting ( blue ) the contributions of antibodies to pathogenesis . Figure 7 : Age - seroprevalence curves for the studies with appropriate , digitizable data on endemic HCoV . Figure 8 : Age - incidence curves for studies with appropriate , digitizable data on endemic HCoV . Figure 9 : Seroprevalence ( shaded area , scale indicated by right y - axis ) and seroincidence ( lines , scale indicated by left y - axis ) curves by age for a single strain for four hypothetical models of coronavirus immunity . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 21 Main Text Table Titles Table 1 : Percentage of patients that had detectable antibodies , at different time points post infection , for HCoV - 229E and MERS - CoV . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 22 Supplementary Figure Titles Figure S1 : Cumulative proportion of patients that seroconverted . Figure S2 : Antibody time series reported in studies in units of optical density ( OD ) . Figure S3 : Antibody time series reported in studies in units of titers . Supplementary Table Titles Table S1 : Summary of serological Assays Table S2 : Summary of studies on the kinetics of antibody immunity after infection , and for the association of antibody responses with disease severity . Table S3 : Severity ratings used in the studies , and the corresponding standardisations . Table S4 : Summary of studies on correlates of antibody immunity and protection against CoVs infection . Table S5 : Summary of studies on antigenic diversity , cross - reactivity . Table S6 : Summary of immunopathogenesis . Table S7 : Summary of studies on population - level seroprevalence of CoV . Table S8 : Estimated annual force of infection from digitized age - seroprevalence data for endemic HCoVs . Supplementary Data Titles Supplementary Data S1 : Data digitized on antibody kinetics and association of antibody responses with clinical severity . Supplementary Data S2 : Data digitized on cross - reactivity and antigenic diversity . Supplementary Data S3 : Data digitized on population seroprevalence . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 23 References 1 . Chinazzi , M . et al . The effect of travel restrictions on the spread of the 2019 novel coronavirus ( COVID - 19 ) outbreak . Science ( 2020 ) doi : 10 . 1126 / science . aba9757 . 2 . Read , J . M . , Bridgen , J . R . E . , Cummings , D . A . T . , Ho , A . & Jewell , C . P . Novel coronavirus 2019 - nCoV : early estimation of epidemiological parameters and epidemic predictions . doi : 10 . 1101 / 2020 . 01 . 23 . 20018549 . 3 . Kucharski , A . J . et al . Early dynamics of transmission and control of COVID - 19 : a mathematical modelling study . Lancet Infect . Dis . ( 2020 ) doi : 10 . 1016 / S1473 - 3099 ( 20 ) 30144 - 4 . 4 . Casadevall , A . & Pirofski , L . - A . The convalescent sera option for containing COVID - 19 . J . Clin . Invest . 130 , 1545 â€“ 1548 ( 2020 ) . 5 . Godlee , F . The burning building . BMJ m1101 ( 2020 ) doi : 10 . 1136 / bmj . m1101 . 6 . Baker , R . E . , Yang , W . , Vecchi , G . A . , Metcalf , C . J . E . & Grenfell , B . T . Susceptible supply limits the role of climate in the COVID - 19 pandemic . doi : 10 . 1101 / 2020 . 04 . 03 . 20052787 . 7 . Kissler , S . M . , Tedijanto , C . , Goldstein , E . , Grad , Y . H . & Lipsitch , M . Projecting the transmission dynamics of SARS - CoV - 2 through the post - pandemic period . Epidemiology ( 2020 ) . 8 . Callow , K . A . , Parry , H . F . , Sergeant , M . & Tyrrell , D . A . The time course of the immune response to experimental coronavirus infection of man . Epidemiol . Infect . 105 , 435 â€“ 446 ( 1990 ) . 9 . Reed , S . E . The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers : evidence of heterogeneity among 229E - related strains . J . Med . Virol . 13 , 179 â€“ 192 ( 1984 ) . 10 . Bradburne , A . F . , Bynoe , M . L . & Tyrrell , D . A . Effects of a â€˜newâ€™ human respiratory virus in volunteers . BMJ vol . 3 767 â€“ 769 ( 1967 ) . 11 . Tyrrell , D . A . & Bynoe , M . L . CULTIVATION OF A NOVEL TYPE OF COMMON - COLD . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 24 VIRUS IN ORGAN CULTURES . Br . Med . J . 1 , 1467 â€“ 1470 ( 1965 ) . 12 . Callow , K . A . Effect of specific humoral immunity and some non - specific factors on resistance of volunteers to respiratory coronavirus infection . J . Hyg . 95 , 173 â€“ 189 ( 1985 ) . 13 . Eyal , N . , Lipsitch , M . & Smith , P . G . Human challenge studies to accelerate coronavirus vaccine licensure . J . Infect . Dis . ( 2020 ) doi : 10 . 1093 / infdis / jiaa152 . 14 . Ferguson , N . M . et al . EPIDEMIOLOGY . Countering the Zika epidemic in Latin America . Science 353 , 353 â€“ 354 ( 2016 ) . 15 . Borchering , R . K . et al . Impacts of Zika emergence in Latin America on endemic dengue transmission . Nat . Commun . 10 , 5730 ( 2019 ) . 16 . He , D . et al . Global Spatio - temporal Patterns of Influenza in the Post - pandemic Era . Sci . Rep . 5 , 11013 ( 2015 ) . 17 . Peiris , J . S . M . et al . Clinical progression and viral load in a community outbreak of coronavirus - associated SARS pneumonia : a prospective study . Lancet 361 , 1767 â€“ 1772 ( 2003 ) . 18 . Hens , N . et al . Seventy - five years of estimating the force of infection from current status data . Epidemiol . Infect . 138 , 802 â€“ 812 ( 2010 ) . 19 . Chen , X . et al . Serology of severe acute respiratory syndrome : implications for surveillance and outcome . J . Infect . Dis . 189 , 1158 â€“ 1163 ( 2004 ) . 20 . Hsueh , P . - R . , Huang , L . - M . , Chen , P . - J . , Kao , C . - L . & Yang , P . - C . Chronological evolution of IgM , IgA , IgG and neutralisation antibodies after infection with SARS - associated coronavirus . Clin . Microbiol . Infect . 10 , 1062 â€“ 1066 ( 2004 ) . 21 . Yang , Z . et al . Determining SARS sub - clinical infection : a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital . Scand . J . Infect . Dis . 41 , 507 â€“ 510 ( 2009 ) . 22 . He , W . - P . , Shu , C . - L . , Li , B . - A . , Zhao , J . & Cheng , Y . Human LINE1 endonuclease domain as a putative target of SARS - associated autoantibodies involved in the pathogenesis of . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 25 severe acute respiratory syndrome . Chin . Med . J . 121 , 608 â€“ 614 ( 2008 ) . 23 . Spanakis , N . et al . Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen . Int . J . Antimicrob . Agents 44 , 528 â€“ 532 ( 2014 ) . 24 . Ko , J . - H . et al . Serologic responses of 42 MERS - coronavirus - infected patients according to the disease severity . Diagn . Microbiol . Infect . Dis . 89 , 106 â€“ 111 ( 2017 ) . 25 . Hsueh , P . - R . et al . Microbiologic characteristics , serologic responses , and clinical manifestations in severe acute respiratory syndrome , Taiwan . Emerg . Infect . Dis . 9 , 1163 â€“ 1167 ( 2003 ) . 26 . Hsueh , P . - R . , Huang , L . - M . , Chen , P . - J . , Kao , C . - L . & Yang , P . - C . Chronological evolution of IgM , IgA , IgG and neutralisation antibodies after infection with SARS - associated coronavirus . Clin . Microbiol . Infect . 10 , 1062 â€“ 1066 ( 2004 ) . 27 . Park , W . B . et al . Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans , South Korea . Emerg . Infect . Dis . 21 , 2186 â€“ 2189 ( 2015 ) . 28 . Azhar , E . I . et al . Evidence for camel - to - human transmission of MERS coronavirus . N . Engl . J . Med . 370 , 2499 â€“ 2505 ( 2014 ) . 29 . Wang , W . L . et al . Serological Study of An Imported Case of Middle East Respiratory Syndrome and His Close Contacts in China , 2015 . Biomed . Environ . Sci . 29 , 219 â€“ 223 ( 2016 ) . 30 . Al - Abdely , H . M . et al . Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients , Saudi Arabia . Emerg . Infect . Dis . 25 , 753 â€“ 766 ( 2019 ) . 31 . Yang , Z . et al . Determining SARS sub - clinical infection : a longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital . Scand . J . Infect . Dis . 41 , 507 â€“ 510 ( 2009 ) . 32 . Hsueh , P . - R . , Huang , L . - M . , Chen , P . - J . , Kao , C . - L . & Yang , P . - C . Chronological evolution . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 26 of IgM , IgA , IgG and neutralisation antibodies after infection with SARS - associated coronavirus . Clin . Microbiol . Infect . 10 , 1062 â€“ 1066 ( 2004 ) . 33 . Tan , W . et al . Viral Kinetics and Antibody Responses in Patients with COVID - 19 . medRxiv ( 2020 ) . 34 . Zhao , J . et al . Antibody Responses to SARS - CoV - 2 in Patients of Novel Coronavirus Disease 2019 . Preprint with The Lancet ( 2020 ) . 35 . Van Kerkhove , M . D . et al . Transmissibility of MERS - CoV Infection in Closed Setting , Riyadh , Saudi Arabia , 2015 . Emerg . Infect . Dis . 25 , 1802 â€“ 1809 ( 2019 ) . 36 . Tang , F . et al . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome : a six - year follow - up study . J . Immunol . 186 , 7264 â€“ 7268 ( 2011 ) . 37 . Cao , W . - C . , Liu , W . , Zhang , P . - H . , Zhang , F . & Richardus , J . H . Disappearance of antibodies to SARS - associated coronavirus after recovery . N . Engl . J . Med . 357 , 1162 â€“ 1163 ( 2007 ) . 38 . Liu , W . et al . Two - year prospective study of the humoral immune response of patients with severe acute respiratory syndrome . J . Infect . Dis . 193 , 792 â€“ 795 ( 2006 ) . 39 . Chan , K . H . et al . Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross - reactivity with human coronaviruses 229E , OC43 , and NL63 . Clin . Diagn . Lab . Immunol . 12 , 1317 â€“ 1321 ( 2005 ) . 40 . Choe , P . G . et al . MERS - CoV Antibody Responses 1 Year after Symptom Onset , South Korea , 2015 . Emerg . Infect . Dis . 23 , 1079 â€“ 1084 ( 2017 ) . 41 . Cao , W . - C . , Liu , W . , Zhang , P . - H . , Zhang , F . & Richardus , J . H . Disappearance of antibodies to SARS - associated coronavirus after recovery . N . Engl . J . Med . 357 , 1162 â€“ 1163 ( 2007 ) . 42 . Park , W . B . et al . Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans , South Korea . Emerg . Infect . Dis . 21 , 2186 â€“ 2189 ( 2015 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 27 43 . Choe , P . G . et al . MERS - CoV Antibody Responses 1 Year after Symptom Onset , South Korea , 2015 . Emerg . Infect . Dis . 23 , 1079 â€“ 1084 ( 2017 ) . 44 . Ko , J . - H . et al . Serologic responses of 42 MERS - coronavirus - infected patients according to the disease severity . Diagn . Microbiol . Infect . Dis . 89 , 106 â€“ 111 ( 2017 ) . 45 . Kraaijeveld , C . A . , Reed , S . E . & Macnaughton , M . R . Enzyme - linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus strain 229 E . J . Clin . Microbiol . 12 , 493 â€“ 497 ( 1980 ) . 46 . Ko , J . - H . et al . Serologic responses of 42 MERS - coronavirus - infected patients according to the disease severity . Diagn . Microbiol . Infect . Dis . 89 , 106 â€“ 111 ( 2017 ) . 47 . Okba , N . M . A . et al . Sensitive and Specific Detection of Low - Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections . Emerg . Infect . Dis . 25 , 1868 â€“ 1877 ( 2019 ) . 48 . Choe , P . G . et al . MERS - CoV Antibody Responses 1 Year after Symptom Onset , South Korea , 2015 . Emerg . Infect . Dis . 23 , 1079 â€“ 1084 ( 2017 ) . 49 . Al Hosani , F . I . et al . Serologic Follow - up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts - Abu Dhabi , United Arab Emirates . Clin . Infect . Dis . 68 , 409 â€“ 418 ( 2019 ) . 50 . Barrow , G . I . et al . The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers . Clin . Exp . Allergy 20 , 45 â€“ 51 ( 1990 ) . 51 . Hamre , D . & Beem , M . Virologic studies of acute respiratory disease in young adults . V . Coronavirus 229E infections during six years of surveillance . Am . J . Epidemiol . 96 , 94 â€“ 106 ( 1972 ) . 52 . Perlman , S . & Dandekar , A . A . Immunopathogenesis of coronavirus infections : implications for SARS . Nat . Rev . Immunol . 5 , 917 â€“ 927 ( 2005 ) . 53 . Resta , S . , Luby , J . P . , Rosenfeld , C . R . & Siegel , J . D . Isolation and propagation of a human enteric coronavirus . Science 229 , 978 â€“ 981 ( 1985 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 28 54 . Gerna , G . , Passarani , N . , Cereda , P . M . & Battaglia , M . Antigenic relatedness of human enteric coronavirus strains to human coronavirus OC43 : a preliminary report . J . Infect . Dis . 150 , 618 â€“ 619 ( 1984 ) . 55 . Han , M . G . , Cheon , D . - S . , Zhang , X . & Saif , L . J . Cross - protection against a human enteric coronavirus and a virulent bovine enteric coronavirus in gnotobiotic calves . J . Virol . 80 , 12350 â€“ 12356 ( 2006 ) . 56 . Gerdes , J . C . , Klein , I . , DeVald , B . L . & Burks , J . S . Coronavirus isolates SK and SD from multiple sclerosis patients are serologically related to murine coronaviruses A59 and JHM and human coronavirus OC43 , but not to human coronavirus 229E . J . Virol . 38 , 231 â€“ 238 ( 1981 ) . 57 . Kaye , H . S . , Yarbrough , W . B . , Reed , C . J . & Harrison , A . K . Antigenic relationship between human coronavirus strain OC 43 and hemagglutinating encephalomyelitis virus strain 67N of swine : antibody responses in human and animal sera . J . Infect . Dis . 135 , 201 â€“ 209 ( 1977 ) . 58 . Vlasova , A . N . et al . Two - way antigenic cross - reactivity between severe acute respiratory syndrome coronavirus ( SARS - CoV ) and group 1 animal CoVs is mediated through an antigenic site in the N - terminal region of the SARS - CoV nucleoprotein . J . Virol . 81 , 13365 â€“ 13377 ( 2007 ) . 59 . Zhong , X . et al . B - cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein . J . Virol . 79 , 3401 â€“ 3408 ( 2005 ) . 60 . Cui , J . , Li , F . & Shi , Z . - L . Origin and evolution of pathogenic coronaviruses . Nat . Rev . Microbiol . 17 , 181 â€“ 192 ( 2019 ) . 61 . Bisht , H . et al . Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice . Proc . Natl . Acad . Sci . U . S . A . 101 , 6641 â€“ 6646 ( 2004 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 29 62 . Ren , Y . et al . A strategy for searching antigenic regions in the SARS - CoV spike protein . Genomics Proteomics Bioinformatics 1 , 207 â€“ 215 ( 2003 ) . 63 . Meyer , B . , Drosten , C . & MÃ¼ller , M . A . Serological assays for emerging coronaviruses : challenges and pitfalls . Virus Res . 194 , 175 â€“ 183 ( 2014 ) . 64 . Grifoni , A . et al . A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS - CoV - 2 . Cell Host Microbe 27 , 671 â€“ 680 . e2 ( 2020 ) . 65 . Bradburne , A . F . Antigenic relationships amongst coronaviruses . Arch . Gesamte Virusforsch . 31 , 352 â€“ 364 ( 1970 ) . 66 . Trivedi , S . U . et al . Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses . Sci . Rep . 9 , 1390 ( 2019 ) . 67 . Agnihothram , S . et al . Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses . J . Infect . Dis . 209 , 995 â€“ 1006 ( 2014 ) . 68 . Gao , X . et al . Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection . J . Infect . 71 , 599 â€“ 602 ( 2015 ) . 69 . Kaye , H . S . , Ong , S . B . & Dowdle , W . R . Detection of coronavirus 229E antibody by indirect hemagglutination . Appl . Microbiol . 24 , 703 â€“ 707 ( 1972 ) . 70 . Dijkman , R . et al . Human coronavirus NL63 and 229E seroconversion in children . J . Clin . Microbiol . 46 , 2368 â€“ 2373 ( 2008 ) . 71 . Dijkman , R . et al . The dominance of human coronavirus OC43 and NL63 infections in infants . J . Clin . Virol . 53 , 135 â€“ 139 ( 2012 ) . 72 . Lehmann , C . et al . A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses . Diagn . Microbiol . Infect . Dis . 61 , 40 â€“ 48 ( 2008 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 30 73 . Che , X . - Y . et al . Antigenic cross - reactivity between severe acute respiratory syndrome - associated coronavirus and human coronaviruses 229E and OC43 . J . Infect . Dis . 191 , 2033 â€“ 2037 ( 2005 ) . 74 . Liang , F . - Y . et al . Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot : implications for the diagnosis of coronavirus infection . J . Virol . Methods 187 , 413 â€“ 420 ( 2013 ) . 75 . Patrick , D . M . et al . An Outbreak of Human Coronavirus OC43 Infection and Serological Cross - reactivity with SARS Coronavirus . Can . J . Infect . Dis . Med . Microbiol . 17 , 330 â€“ 336 ( 2006 ) . 76 . Chan , K . - H . et al . Cross - reactive antibodies in convalescent SARS patientsâ€™ sera against the emerging novel human coronavirus EMC ( 2012 ) by both immunofluorescent and neutralizing antibody tests . J . Infect . 67 , 130 â€“ 140 ( 2013 ) . 77 . Aburizaiza , A . S . et al . Investigation of anti - middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah , Saudi Arabia , fall 2012 . J . Infect . Dis . 209 , 243 â€“ 246 ( 2014 ) . 78 . Yu , Y . et al . Childrenâ€™s vaccines do not induce cross reactivity against SARS - CoV . J . Clin . Pathol . 60 , 208 â€“ 211 ( 2007 ) . 79 . Trivedi , S . U . et al . Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses . Sci . Rep . 9 , 1390 ( 2019 ) . 80 . Du , L . , Ma , C . & Jiang , S . Antibodies induced by receptor - binding domain in spike protein of SARS - CoV do not cross - neutralize the novel human coronavirus hCoV - EMC . The Journal of infection vol . 67 348 â€“ 350 ( 2013 ) . 81 . Yu , F . et al . Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein - based enzyme - linked immunosorbent assay . Clin . Diagn . Lab . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 31 Immunol . 12 , 848 â€“ 854 ( 2005 ) . 82 . Mu , F . et al . The expression and antigenicity of a truncated spike - nucleocapsid fusion protein of severe acute respiratory syndrome - associated coronavirus . BMC Microbiol . 8 , 207 ( 2008 ) . 83 . He , Y . , Zhou , Y . , Siddiqui , P . , Niu , J . & Jiang , S . Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome - associated coronavirus . J . Clin . Microbiol . 43 , 3718 â€“ 3726 ( 2005 ) . 84 . Carattoli , A . et al . Recombinant protein - based ELISA and immuno - cytochemical assay for the diagnosis of SARS . J . Med . Virol . 76 , 137 â€“ 142 ( 2005 ) . 85 . Rockx , B . et al . Structural basis for potent cross - neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge . J . Virol . 82 , 3220 â€“ 3235 ( 2008 ) . 86 . Zhu , Z . et al . Potent cross - reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies . Proc . Natl . Acad . Sci . U . S . A . 104 , 12123 â€“ 12128 ( 2007 ) . 87 . Yang , Z . - Y . et al . Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses . Proc . Natl . Acad . Sci . U . S . A . 102 , 797 â€“ 801 ( 2005 ) . 88 . Liu , L . et al . Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross - neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus . J . Virol . 81 , 4694 â€“ 4700 ( 2007 ) . 89 . He , Y . et al . Cross - neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor - binding domain of spike protein . J . Immunol . 176 , 6085 â€“ 6092 ( 2006 ) . 90 . Elshabrawy , H . A . , Coughlin , M . M . , Baker , S . C . & Prabhakar , B . S . Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS - CoV spike protein are more broadly neutralizing . PLoS One 7 , e50366 ( 2012 ) . 91 . Tian , X . et al . Potent binding of 2019 novel coronavirus spike protein by a SARS . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 32 coronavirus - specific human monoclonal antibody . Emerg . Microbes Infect . 9 , 382 â€“ 385 ( 2020 ) . 92 . Tai , W . et al . Recombinant Receptor - Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses ( MERS - CoVs ) Induce Cross - Neutralizing Antibodies against Divergent Human and Camel MERS - CoVs and Antibody Escape Mutants . J . Virol . 91 , ( 2017 ) . 93 . Agnihothram , S . et al . Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses . J . Infect . Dis . 209 , 995 â€“ 1006 ( 2014 ) . 94 . Peiris , J . S . M . et al . Clinical progression and viral load in a community outbreak of coronavirus - associated SARS pneumonia : a prospective study . Lancet 361 , 1767 â€“ 1772 ( 2003 ) . 95 . Ho , M . - S . et al . Neutralizing antibody response and SARS severity . Emerg . Infect . Dis . 11 , 1730 â€“ 1737 ( 2005 ) . 96 . Kliks , S . C . , Nimmanitya , S . , Nisalak , A . & Burke , D . S . Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants . Am . J . Trop . Med . Hyg . 38 , 411 â€“ 419 ( 1988 ) . 97 . Weiss , R . C . & Scott , F . W . Antibody - mediated enhancement of disease in feline infectious peritonitis : comparisons with dengue hemorrhagic fever . Comp . Immunol . Microbiol . Infect . Dis . 4 , 175 â€“ 189 ( 1981 ) . 98 . Talbot , H . K . et al . The pediatric burden of human coronaviruses evaluated for twenty years . Pediatr . Infect . Dis . J . 28 , 682 â€“ 687 ( 2009 ) . 99 . Jaume , M . et al . Anti - severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH - and cysteine protease - independent FcÎ³R pathway . J . Virol . 85 , 10582 â€“ 10597 ( 2011 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 33 100 . Yip , M . S . et al . Antibody - dependent infection of human macrophages by severe acute respiratory syndrome coronavirus . Virol . J . 11 , 82 ( 2014 ) . 101 . Yip , M . S . et al . Antibody - dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS . Hong Kong Med . J . 22 , 25 â€“ 31 ( 2016 ) . 102 . Fu , Y . , Cheng , Y . & Wu , Y . Understanding SARS - CoV - 2 - Mediated Inflammatory Responses : From Mechanisms to Potential Therapeutic Tools . Virol . Sin . ( 2020 ) doi : 10 . 1007 / s12250 - 020 - 00207 - 4 . 103 . Wang , S . - F . et al . Antibody - dependent SARS coronavirus infection is mediated by antibodies against spike proteins . Biochem . Biophys . Res . Commun . 451 , 208 â€“ 214 ( 2014 ) . 104 . Yip , M . S . et al . Antibody - dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS . Hong Kong Med . J . 22 , 25 â€“ 31 ( 2016 ) . 105 . Cameron , M . J . , Bermejo - Martin , J . F . , Danesh , A . , Muller , M . P . & Kelvin , D . J . Human immunopathogenesis of severe acute respiratory syndrome ( SARS ) . Virus Res . 133 , 13 â€“ 19 ( 2008 ) . 106 . Lin , Y . S . et al . Antibody to severe acute respiratory syndrome ( SARS ) - associated coronavirus spike protein domain 2 cross - reacts with lung epithelial cells and causes cytotoxicity . Clin . Exp . Immunol . 141 , 500 â€“ 508 ( 2005 ) . 107 . Fang , Y . - T . et al . Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome - associated coronavirus spike domain 2 antibodies . Mol . Immunol . 47 , 1000 â€“ 1009 ( 2010 ) . 108 . Cheng , M . et al . Cross - reactivity of antibody against SARS - coronavirus nucleocapsid protein with IL - 11 . Biochem . Biophys . Res . Commun . 338 , 1654 â€“ 1660 ( 2005 ) . 109 . Yasmon , A . , Ibrahim , F . , Bela , B . & Sjahrurachman , A . Potential cross - reactivity of severe acute respiratory syndrome - associated coronavirus ( SARS - CoV ) nucleocapsid ( N ) - based IgG ELISA assay for plasma samples from HIV - 1 positive intravenous drug users ( IDUs ) . Acta Med . Indones . 44 , 193 â€“ 198 ( 2012 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 34 110 . Cavallaro , J . J . & Monto , A . S . Community - wide outbreak of infection with a 229E - like coronavirus in Tecumseh , Michigan . J . Infect . Dis . 122 , 272 â€“ 279 ( 1970 ) . 111 . Sarateanu , D . E . & Ehrengut , W . A two year serological surveillance of coronavirus infections in Hamburg . Infection 8 , 70 â€“ 72 ( 1980 ) . 112 . Shao , X . , Guo , X . , Esper , F . , Weibel , C . & Kahn , J . S . Seroepidemiology of group I human coronaviruses in children . J . Clin . Virol . 40 , 207 â€“ 213 ( 2007 ) . 113 . Severance , E . G . et al . Development of a nucleocapsid - based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U . S . metropolitan population . Clin . Vaccine Immunol . 15 , 1805 â€“ 1810 ( 2008 ) . 114 . Chan , C . M . et al . Examination of seroprevalence of coronavirus HKU1 infection with S protein - based ELISA and neutralization assay against viral spike pseudotyped virus . J . Clin . Virol . 45 , 54 â€“ 60 ( 2009 ) . 115 . Zhou , W . , Wang , W . , Wang , H . , Lu , R . & Tan , W . First infection by all four non - severe acute respiratory syndrome human coronaviruses takes place during childhood . BMC Infect . Dis . 13 , 433 ( 2013 ) . 116 . Hovi , T . , Kainulainen , H . , Ziola , B . & Salmi , A . OC43 strain - related coronavirus antibodies in different age groups . J . Med . Virol . 3 , 313 â€“ 320 ( 1979 ) . 117 . Ukkonen , P . , Hovi , T . , von Bonsdorff , C . H . , Saikku , P . & Penttinen , K . Age - specific prevalence of complement - fixing antibodies to sixteen viral antigens : a computer analysis of 58 , 500 patients covering a period of eight years . J . Med . Virol . 13 , 131 â€“ 148 ( 1984 ) . 118 . Monto , A . S . & Lim , S . K . The Tecumseh study of respiratory illness . VI . Frequency of and relationship between outbreaks of coronavirus infection . J . Infect . Dis . 129 , 271 â€“ 276 ( 1974 ) . 119 . Schmidt , O . W . , Allan , I . D . , Cooney , M . K . , Foy , H . M . & Fox , J . P . Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975 - 1979 . Am . J . Epidemiol . 123 , 862 â€“ 868 ( 1986 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 35 120 . Walsh , E . E . , Shin , J . H . & Falsey , A . R . Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations . J . Infect . Dis . 208 , 1634 â€“ 1642 ( 2013 ) . 121 . Falsey , A . R . , Walsh , E . E . & Hayden , F . G . Rhinovirus and coronavirus infection - associated hospitalizations among older adults . J . Infect . Dis . 185 , 1338 â€“ 1341 ( 2002 ) . 122 . Falsey , A . R . et al . Long - term care facilities : a cornucopia of viral pathogens . J . Am . Geriatr . Soc . 56 , 1281 â€“ 1285 ( 2008 ) . 123 . Gorse , G . J . , Donovan , M . M . & Patel , G . B . Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus - associated illnesses . J . Med . Virol . 92 , 512 â€“ 517 ( 2020 ) . 124 . Gaunt , E . R . , Hardie , A . , Claas , E . C . J . , Simmonds , P . & Templeton , K . E . Epidemiology and clinical presentations of the four human coronaviruses 229E , HKU1 , NL63 , and OC43 detected over 3 years using a novel multiplex real - time PCR method . J . Clin . Microbiol . 48 , 2940 â€“ 2947 ( 2010 ) . 125 . Leung , G . M . et al . Seroprevalence of IgG antibodies to SARS - coronavirus in asymptomatic or subclinical population groups . Epidemiol . Infect . 134 , 211 â€“ 221 ( 2006 ) . 126 . MÃ¼ller , M . A . et al . Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia : a nationwide , cross - sectional , serological study . Lancet Infect . Dis . 15 , 559 â€“ 564 ( 2015 ) . 127 . Degnah , A . A . et al . Seroprevalence of MERS - CoV in healthy adults in western Saudi Arabia , 2011 - 2016 . J . Infect . Public Health ( 2020 ) doi : 10 . 1016 / j . jiph . 2020 . 01 . 001 . 128 . Sikkema , R . S . et al . Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013 - 2014 : A Case - Control Study . J . Infect . Dis . 215 , 1702 â€“ 1705 ( 2017 ) . 129 . Alshukairi , A . N . et al . High Prevalence of MERS - CoV Infection in Camel Workers in Saudi Arabia . MBio 9 , ( 2018 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 36 130 . Khudhair , A . et al . Risk Factors for MERS - CoV Seropositivity among Animal Market and Slaughterhouse Workers , Abu Dhabi , United Arab Emirates , 2014 - 2017 . Emerg . Infect . Dis . 25 , 927 â€“ 935 ( 2019 ) . 131 . Wu , J . T . et al . Estimating clinical severity of COVID - 19 from the transmission dynamics in Wuhan , China . doi : 10 . 21203 / rs . 3 . rs - 17453 / v1 . 132 . Thanh Le , T . et al . The COVID - 19 vaccine development landscape . Nat . Rev . Drug Discov . ( 2020 ) doi : 10 . 1038 / d41573 - 020 - 00073 - 5 . 133 . Jiang , S . , Hillyer , C . & Du , L . Neutralizing Antibodies against SARS - CoV - 2 and Other Human Coronaviruses . Trends Immunol . ( 2020 ) doi : 10 . 1016 / j . it . 2020 . 03 . 007 . 134 . Cao , X . COVID - 19 : immunopathology and its implications for therapy . Nat . Rev . Immunol . ( 2020 ) doi : 10 . 1038 / s41577 - 020 - 0308 - 3 . 135 . Zhang , W . et al . Molecular and serological investigation of 2019 - nCoV infected patients : implication of multiple shedding routes . Emerg . Microbes Infect . 9 , 386 â€“ 389 ( 2020 ) . 136 . Tsao , K . - C . et al . False positive antibody results against human T - cell lymphotropic virus in patients with severe acute respiratory syndrome . J . Med . Virol . 77 , 331 â€“ 336 ( 2005 ) . 137 . Chen , X . et al . Serology of severe acute respiratory syndrome : implications for surveillance and outcome . J . Infect . Dis . 189 , 1158 â€“ 1163 ( 2004 ) . 138 . Hsueh , P . - R . et al . Microbiologic characteristics , serologic responses , and clinical manifestations in severe acute respiratory syndrome , Taiwan . Emerg . Infect . Dis . 9 , 1163 â€“ 1167 ( 2003 ) . 139 . Chan , K . - H . et al . Cross - reactive antibodies in convalescent SARS patientsâ€™ sera against the emerging novel human coronavirus EMC ( 2012 ) by both immunofluorescent and neutralizing antibody tests . J . Infect . 67 , 130 â€“ 140 ( 2013 ) . 140 . Haynes , L . M . et al . Recombinant protein - based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins . Clin . Vaccine Immunol . 14 , 331 â€“ 333 ( 2007 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 37 141 . Viruses , C . S . G . of T . I . C . on T . of & Coronaviridae Study Group of the International Committee on Taxonomy of Viruses . The species Severe acute respiratory syndrome - related coronavirus : classifying 2019 - nCoV and naming it SARS - CoV - 2 . Nature Microbiology vol . 5 536 â€“ 544 ( 2020 ) . 142 . Al - Abdely , H . M . et al . Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients , Saudi Arabia . Emerg . Infect . Dis . 25 , 753 â€“ 766 ( 2019 ) . 143 . Alshukairi , A . N . et al . Antibody Response and Disease Severity in Healthcare Worker MERS Survivors . Emerg . Infect . Dis . 22 , ( 2016 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint Table 1 : Proportion of patients that had detectable antibodies , at different time points post symptom onset or infection , for HCoV - 229E and MERS - CoV . Results for HCoV - 229E are from Kraaijeveld et al . 45 , and report the number of individuals experiencing symptoms of a given severity that had significant antibody rises post infection . Results for MERS - CoV are taken across studies in which a cutoff for the assay being used was provided , and gives the number of patients for which IgG levels were above the respective cutoffs , at different time points ( also see Figure 4 ) . For example , at week 26 , there were 12 patients with mild symptoms from studies that reported a cutoff , and 8 of those patients had IgG levels above that cutoff . MERS - CoV data were digitised from six studies 35 , 40 , 46 , 47 , 142 , 143 Asymptomatic Mild symptoms Severe symptoms HCov - 229E 3 weeks 20 % ( 1 of 5 ) 100 % ( 10 of 10 ) MERS - CoV 13 weeks 67 % ( 10 of 15 ) 95 % ( 18 of 19 ) 26 weeks 67 % ( 8 of 12 ) 100 % ( 10 of 10 ) 52 weeks 67 % ( 8 of 12 ) 100 % ( 8 of 8 ) . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint 1st infection 2nd infection Antibody ( = Immunity ? ) High Low Severe disease Antibodykinetics Correlates of protection Low antibody - level High antibody - level Population seroprevalence Time Immunopathogenesis ? Antigenic diversity & cross - reactivity S e r o p r e v a l e n c e may bias measured seroprevalence Endemic HCoVs SARS - CoV - 2 Time Antigenic diversity & cross - reactivity S e r o p r e v a l e n c e Underestimated transmission due to loss of seropositivity Endemic HCoVs SARS - CoV - 2 Time Low Figure 1 : Aspects of antibody response included in this review . This figure shows the areas of focus of our review within our conceptualisation of the stages of exposure and infection at which we believe antibody mediated immunity may play a role in the dynamics of SARS - CoV - 2 . At the individual level ( left ) , antibody response following the first infection / exposure increases and then declines ( Antibody kinetics ) . Sometime later individuals may be exposed to SARS - CoV - 2 again . They may be protected from infection by their acquired immunity ( Correlates of protection ) . Their acquired immunity may also moderate the severity of infection with some possibility that pre - existing immunity may lead to immunopathogenesis ( relevant to both first and second exposure ) . These individual - level dynamics aggregate to form the population - level seroprevalence ( right - top ) . Measures of seroprevalence may imperfectly measure past exposure to infection due to antigenic diversity of future SARS - CoV - 2 viruses and cross - reactivity of endemic human coronaviruses ( HCoVs ) with SARS - CoV - 2 . Measures of seroprevalence may also be inconsistent across times as antibodies - levels within individuals wane . . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t Records identified through Pubmed searches ( N = 1477 ) Full - text excluded as did not match tags ( N = 119 ) Full - text articles assessed for eligibility ( N = 322 ) Abstracts excluded ( N = 959 ) 109 human CoV without immunity 758 animal / lab studies 81 not CoV 7 foreign language 1 duplicate 3 bad record / dead link Records identified through citations and expert consultation ( N = 37 ) Abstracts screened ( N = 1281 ) Records after duplicates removed ( N = 1281 ) Studies included in qualitative synthesis ( N = 203 ) Studies included in quantitative synthesis ( pooled analyses ) ( N = 40 ) I D E N T I F I C A T I O N I N C L U S I O N E L I G I B I L I T Y S C R EE N I N G Figure 2 : PRISMA diagram of systematic review process . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint MERS âˆ’ CoV SARS âˆ’ CoV âˆ’ 1 SARS âˆ’ CoV âˆ’ 2 I g G I g M N e u t r a li z i ng 0 10 20 30 40 0 10 20 30 40 0 10 20 30 40 0 10 20 0 10 20 30 0 10 20 30 Time from symptom onset or infection ( days ) C oun t Severity No severity reported Mild Severe Figure 3 : Distributions of times from symptom onset to detection of antibodies against MERS , SARS - CoV - 1 and SARS - CoV - 2 . Times between symptom onset and the detection of IgG ( top row ) , IgM ( middle row ) and neutralizing antibodies ( bottom row ) . Black vertical lines indicate the median values across all severity ratings , while dashed coloured lines are the median values for mild ( blue ) , severe ( orange ) illnesses as well as illnesses of unreported severity ( grey ) . Data were digitized from 12 studies 23 , 27 , 29 , 30 , 32 , 34 , 40 , 44 , 135 â€“ 138 . . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t â— â— â— â— â— â— â—â—â—â—â—â—â—â—â—â—â—â— â— â—â—â—â— â—â—â— â—â—â—â—â— â— â—â—â—â—â—â—â— â— â—â—â—â— â— â—â—â—â—â—â—â—â—â—â— â— â—â—â—â—â—â—â—â— â—â—â—â—â—â— â— â— â— â— â— â—â—â—â— â— â— â— â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— IgG 0 20 40 60 0 2 4 6 Time from symptom onset or infection ( weeks ) A n t i bod y c on c en t r a t i on ( O D v a l ue s ) â—â— â— â— â— â— â— â— â— Neutralizing 0 20 40 60 10 50 100 500 1000 5000 10000 Time from symptom onset or infection ( weeks ) A n t i bod i e s ( t i t e r s ) Severity â— â— â— No severity reported Mild Severe Cutoff â— < cutoff > = cutoff Unknown PMID 26583829 27109133 28585916 28821364 30882305 31423970 31423971 Figure 4 : MERS - CoV antibody kinetics . The left panel shows data for studies reporting IgG concentration in units of optical density , while the right panel shows data for studies reporting neutralizing antibodies in units of titers . The plotting symbols indicate whether a measurement was above the cutoff for the assay being used , if reported in the study . Some studies reported titers that were lower than or greater than some threshold value ; those are here plotted at those values ( e . g . , for â‰¥ 320 , the value is assumed to be 320 ) . Some studies may report kinetics of different antibodies or using different assays ( and different units ) for the same patient . Note that while these are plotted on the same axes , values may not necessarily be comparable across studies within each panel , as each lab may have different assay conditions resulting in different scales . See Figures S2 and S3 for ( more limited ) data on SARS - CoV - 1 and IgA . . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t (cid:4) (cid:3) (cid:5) (cid:6)(cid:16)(cid:19)(cid:14)(cid:11)(cid:2)(cid:8)(cid:18)(cid:10) (cid:7)(cid:12)(cid:20)(cid:11)(cid:2)(cid:8)(cid:18)(cid:10) (cid:9)(cid:15)(cid:17)(cid:12)(cid:11)(cid:13)(cid:12)(cid:1)(cid:6) (cid:9)(cid:15)(cid:17)(cid:12)(cid:11)(cid:13)(cid:12)(cid:1)(cid:7) (cid:9)(cid:15)(cid:17)(cid:12)(cid:11)(cid:13)(cid:12)(cid:1)(cid:8) (cid:4) (cid:1) (cid:3) (cid:4) (cid:7) (cid:2) (cid:6) (cid:5) (cid:7) (cid:8) homo > hetero homo < hetero HCoV âˆ’ 229E HCoV âˆ’ NL63 HCoV âˆ’ HKU1 HCoV âˆ’ OC43 MERS âˆ’ CoV SARS âˆ’ CoV âˆ’ 1 a n t i âˆ’ HC o V âˆ’ 229 E a n t i âˆ’ HC o V âˆ’ O C 43 a n t i âˆ’ S AR S âˆ’ C o V âˆ’ 1 0 3 6 9 0 3 6 9 0 3 6 9 Heterologous log2 ( titer ) H o m o l ogou s l og2 ( t i t e r ) N observations (cid:1) (cid:1) 1 3 5 (cid:1) AcuteConvalescent (cid:1) (cid:1) IFANeutralization ELISA ( against N ) IFA Neutralization a n t i âˆ’ HC o V âˆ’ 229 E a n t i âˆ’ HC o V âˆ’ O C 43 a n t i âˆ’ S AR S âˆ’ C o V âˆ’ 1 1248163264128256 1248163264128256 1248163264128256 Fold ( convalescent : acute ) S e r u m pa i r HCoV âˆ’ 229E HCoV âˆ’ NL63 HCoV âˆ’ OC43 MERS âˆ’ CoV SARS âˆ’ CoV âˆ’ 1 Figure 5 : Antigenic and phylogenetic relationships among human coronaviruses . ( Top ) Reactivity of antiserum ( x - axis ) taken from individuals with confirmed infections of each human coronavirus against a panel of human coronaviruses ( columns ) shown in relation to their phylogeny as measured by IFA ( red ) and neutralization ( purple ) ; convalescent ( circles ) and acute sera ( crosses ) ; size of plot characters denotes the number of observations . The y - axis provides titers to the homologous strain the sera ( rows ) for comparison . ( Bottom ) Bracket of reported convalescent - to - acute titer fold - rise upon infection . Data extracted from 7 studies 39 , 65 , 69 , 72 , 73 , 139 , 140 . Phylogeny modified from 141 . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint (cid:11)(cid:31)(cid:36)(cid:25)(cid:34) (cid:2)(cid:22)(cid:29)(cid:47)(cid:40)(cid:33)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:8)(cid:15)(cid:1)(cid:28)(cid:37)(cid:43)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:11)(cid:3) (cid:21)(cid:25)(cid:35) (cid:16)(cid:46)(cid:1)(cid:39)(cid:42)(cid:49)(cid:1)(cid:16)(cid:30)(cid:1)(cid:31)(cid:42)(cid:41)(cid:31)(cid:33)(cid:41)(cid:46)(cid:44)(cid:29)(cid:46)(cid:37)(cid:42)(cid:41)(cid:45)(cid:2)(cid:27)(cid:29)(cid:41)(cid:35)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:11)(cid:3) (cid:9)(cid:39)(cid:36)(cid:32)(cid:28)(cid:27)(cid:31)(cid:25)(cid:35)(cid:1)(cid:37)(cid:33)(cid:34)(cid:25)(cid:26)(cid:37)(cid:29)(cid:22)(cid:36)(cid:25)(cid:24) (cid:2)(cid:27)(cid:29)(cid:41)(cid:35)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:11)(cid:15)(cid:1)(cid:19)(cid:47)(cid:4)(cid:1)(cid:9)(cid:7)(cid:9)(cid:7)(cid:3) (cid:9)(cid:39)(cid:36)(cid:32)(cid:28)(cid:27)(cid:31)(cid:25)(cid:35)(cid:1)(cid:31)(cid:32)(cid:36)(cid:1)(cid:27)(cid:31)(cid:24)(cid:37)(cid:23)(cid:25)(cid:24) (cid:2)(cid:28)(cid:37)(cid:43)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:13)(cid:3) (cid:16)(cid:32) (cid:16)(cid:46)(cid:1)(cid:36)(cid:37)(cid:35)(cid:36)(cid:1)(cid:16)(cid:30)(cid:1) (cid:31)(cid:42)(cid:41)(cid:31)(cid:33)(cid:41)(cid:46)(cid:44)(cid:29)(cid:46)(cid:37)(cid:42)(cid:41)(cid:45)(cid:1)(cid:2)(cid:27)(cid:29)(cid:41)(cid:35)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:11)(cid:3) (cid:8)(cid:31)(cid:36)(cid:27)(cid:4)(cid:19)(cid:5) (cid:8)(cid:31)(cid:36)(cid:27)(cid:4)(cid:19)(cid:6) (cid:8)(cid:31)(cid:36)(cid:27)(cid:4)(cid:16) (cid:14)(cid:15)(cid:4)(cid:7)(cid:3)(cid:1)(cid:14)(cid:12)(cid:16)(cid:4)(cid:26)(cid:22)(cid:30)(cid:30)(cid:22) (cid:45)(cid:46)(cid:37)(cid:40)(cid:47)(cid:39)(cid:29)(cid:46)(cid:33)(cid:45)(cid:1) (cid:8)(cid:31)(cid:31)(cid:25)(cid:38)(cid:27)(cid:31)(cid:1)(cid:8)(cid:6) (cid:33)(cid:50)(cid:43)(cid:44)(cid:33)(cid:45)(cid:45)(cid:37)(cid:42)(cid:41) (cid:19)(cid:8)(cid:18)(cid:19)(cid:4)(cid:9)(cid:32)(cid:20)(cid:4)(cid:5) (cid:17)(cid:37)(cid:41)(cid:32)(cid:45)(cid:1) (cid:14)(cid:15)(cid:4)(cid:5)(cid:5) (cid:16)(cid:41)(cid:46)(cid:37)(cid:5)(cid:43)(cid:44)(cid:42)(cid:37)(cid:41)(cid:34)(cid:39)(cid:29)(cid:40)(cid:40)(cid:29)(cid:46)(cid:42)(cid:44)(cid:51)(cid:1)(cid:31)(cid:51)(cid:46)(cid:42)(cid:38)(cid:37)(cid:41)(cid:33)(cid:1)(cid:33)(cid:50)(cid:43)(cid:44)(cid:33)(cid:45)(cid:45)(cid:33)(cid:32)(cid:1)(cid:29)(cid:46)(cid:1)(cid:39)(cid:47)(cid:41)(cid:35)(cid:4)(cid:1)(cid:30)(cid:42)(cid:41)(cid:33)(cid:1)(cid:40)(cid:29)(cid:44)(cid:44)(cid:42)(cid:49)(cid:4)(cid:1)(cid:33)(cid:46)(cid:31)(cid:6) (cid:26)(cid:36)(cid:44)(cid:42)(cid:40)(cid:30)(cid:42)(cid:31)(cid:51)(cid:46)(cid:42)(cid:43)(cid:33)(cid:41)(cid:37)(cid:29)(cid:4)(cid:1)(cid:23)(cid:51)(cid:40)(cid:43)(cid:36)(cid:42)(cid:43)(cid:33)(cid:41)(cid:37)(cid:29) (cid:2)(cid:1)(cid:17)(cid:34)(cid:32)(cid:29)(cid:32)(cid:31)(cid:26)(cid:25)(cid:24)(cid:1)(cid:36)(cid:27)(cid:35)(cid:35)(cid:37)(cid:25)(cid:1)(cid:24)(cid:25)(cid:35)(cid:36)(cid:34)(cid:37)(cid:23)(cid:36)(cid:27)(cid:32)(cid:31) (cid:21)(cid:41)(cid:31)(cid:44)(cid:33)(cid:29)(cid:45)(cid:33)(cid:1)(cid:30)(cid:37)(cid:41)(cid:32)(cid:37)(cid:41)(cid:35)(cid:1)(cid:42)(cid:34)(cid:1)(cid:37)(cid:40)(cid:40)(cid:47)(cid:41)(cid:33)(cid:1)(cid:31)(cid:33)(cid:39)(cid:39)(cid:45)(cid:1)(cid:46)(cid:42)(cid:1)(cid:39)(cid:47)(cid:41)(cid:35)(cid:1)(cid:33)(cid:43)(cid:37)(cid:46)(cid:36)(cid:33)(cid:39)(cid:37)(cid:29)(cid:39)(cid:1)(cid:31)(cid:33)(cid:39)(cid:39)(cid:45)(cid:1)(cid:46)(cid:44)(cid:33)(cid:29)(cid:46)(cid:33)(cid:32)(cid:1)(cid:49)(cid:37)(cid:46)(cid:36)(cid:1) (cid:14)(cid:12)(cid:16)(cid:4) (cid:1) (cid:48)(cid:37)(cid:29)(cid:1) (cid:8)(cid:31)(cid:31)(cid:25)(cid:38)(cid:27)(cid:31)(cid:1)(cid:8)(cid:6) (cid:29)(cid:46)(cid:1)(cid:31)(cid:33)(cid:39)(cid:39)(cid:1)(cid:45)(cid:47)(cid:44)(cid:34)(cid:29)(cid:31)(cid:33) (cid:16)(cid:32)(cid:1)(cid:11)(cid:38)(cid:27)(cid:36) (cid:2)(cid:22)(cid:29)(cid:47)(cid:40)(cid:33)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:8)(cid:15)(cid:1)(cid:28)(cid:37)(cid:43)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:11)(cid:3) (cid:2)(cid:23)(cid:37)(cid:41)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:12)(cid:15)(cid:1)(cid:19)(cid:29)(cid:41)(cid:35)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:7)(cid:3) (cid:2)(cid:18)(cid:36)(cid:33)(cid:41)(cid:35)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:12)(cid:15)(cid:1)(cid:28)(cid:29)(cid:45)(cid:40)(cid:42)(cid:41)(cid:4)(cid:1)(cid:9)(cid:7)(cid:8)(cid:9)(cid:3) (cid:11)(cid:31)(cid:24)(cid:25)(cid:30)(cid:27)(cid:23)(cid:1)(cid:13)(cid:9)(cid:32)(cid:20) (cid:2)(cid:20)(cid:42)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:12)(cid:3) (cid:2) (cid:4) (cid:15) (cid:43)(cid:4) (cid:3) (cid:2)(cid:2)(cid:22) (cid:2)(cid:2)(cid:2)(cid:22)(cid:22)(cid:29)(cid:22)(cid:29)(cid:47)(cid:40)(cid:47)(cid:40)(cid:33)(cid:33)(cid:4)(cid:1)(cid:9)(cid:7)(cid:9)(cid:7)(cid:9)(cid:7)(cid:8)(cid:8)(cid:8)(cid:8)(cid:8)(cid:8)(cid:15)(cid:15) (cid:28)(cid:37)(cid:28)(cid:37)(cid:28)(cid:37)(cid:43)(cid:43)(cid:4) (cid:9)(cid:9)(cid:9)(cid:7)(cid:8)(cid:7)(cid:8)(cid:7)(cid:8) (cid:3)(cid:11)(cid:3)(cid:11)(cid:3)(cid:11)(cid:3) (cid:10)(cid:32)(cid:25)(cid:35)(cid:1)(cid:18)(cid:25)(cid:33)(cid:29)(cid:27)(cid:23)(cid:22)(cid:36)(cid:25) (cid:25)(cid:33)(cid:48)(cid:33)(cid:44)(cid:33)(cid:1)(cid:32)(cid:37)(cid:45)(cid:33)(cid:29)(cid:45)(cid:33) (cid:2)(cid:18)(cid:29)(cid:40)(cid:33)(cid:44)(cid:42)(cid:41)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:14)(cid:15)(cid:1)(cid:19)(cid:47)(cid:4)(cid:1)(cid:9)(cid:7)(cid:9)(cid:7)(cid:3) (cid:2)(cid:24)(cid:33)(cid:37)(cid:44)(cid:37)(cid:45)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:10)(cid:15)(cid:1)(cid:20)(cid:45)(cid:47)(cid:33)(cid:36)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:10)(cid:15)(cid:1)(cid:20)(cid:42)(cid:4)(cid:1)(cid:9)(cid:7)(cid:7)(cid:12)(cid:3) (cid:2)(cid:7)(cid:20)(cid:9)(cid:5)(cid:12)(cid:12)(cid:5)(cid:20)(cid:4)(cid:3)(cid:3)(cid:1)(cid:6)(cid:8)(cid:5)(cid:15)(cid:10)(cid:13)(cid:9)(cid:1)(cid:10)(cid:12)(cid:12)(cid:18)(cid:13)(cid:8)(cid:1)(cid:7)(cid:8)(cid:11)(cid:11)(cid:16) (cid:21)(cid:12)(cid:14)(cid:13)(cid:14)(cid:7)(cid:19)(cid:17)(cid:10)(cid:7)(cid:1)(cid:11)(cid:10)(cid:13)(cid:8)(cid:5)(cid:9)(cid:8)(cid:22) Figure 6 : A diagrammatic summary of evidence supporting ( red ) and contradicting ( blue ) the contributions of antibodies to the pathogenesis of SARS - CoV - 1 . Anti - S1 antibodies triggered upon infection may facilitate entry into immune cells at later stages of the infection if concentration is low . Replication happens but no virus is released . Consequential induction of cytokines are inconclusive , but if they occur , they are associated with severe disease . Roles of anti - S2 and anti - N antibodies are supported by binding observations . Items shown in grey are weaker evidence given as speculations in the literature . . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t â— â— â— â— â— â— â— â— â— â— HCoV âˆ’ NL63 HCoV âˆ’ OC43 HCoV âˆ’ 229E HCoV âˆ’ HKU1 0 20 40 60 0 20 40 60 0 . 00 0 . 25 0 . 50 0 . 75 0 . 00 0 . 25 0 . 50 0 . 75 Midpoint of age category S e r op r e v a l en c e Study Cavallaro 1970 ( USA ) Sarateanu 1980 ( Germany ) Shao 2007 ( USA ) Severance 2008 ( USA ) Chan 2009 ( Hong Kong ) Liang 2013 ( Taiwan ) Zhou 2013 ( China ) Assay â— â— ELISA ( NS ) HAI ( NS ) IFA ( IgG ) IFA ( IgM ) Neutralization ( NS ) Western Blot ( NS ) Figure 7 : Age - seroprevalence curves for the studies with appropriate , digitizable data on endemic HCoV . The color denotes the study , and the point type denotes the assay and antibody measured . Data from Sarateanu et al is averaged over two serosurveys conducted in 1975 and 1976 . Data from Liang et al . were measured in cord blood samples and adults aged 18 - 25 , and do not represent the change in seroprevalence across childhood . Therefore we have not connected these two points with a line . . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t â— â— â— â— â— â— â— HCoV âˆ’ 229E HCoV âˆ’ OC43 0 20 40 60 0 20 40 60 0 . 00 0 . 25 0 . 50 Midpoint of age category S e r o i n c i den c e Study Cavallaro 1970 ( USA ) Monto 1974 ( USA ) Schmidt 1986 ( USA ) Walsh 2013 ( USA ) Assay â— CF ( NS ) CF or HAI ( NS ) EIA ( NS ) or PCR ELISA ( IgG ) Neutralization ( NS ) Years of follow âˆ’ up 1 3 4 Figure 8 : Age - incidence curves for studies with appropriate , digitizable data on endemic HCoV . The color denotes the study , the point type denotes the assay and antibody measured , and the line type represents the number of years between successive serosample . CC - BY - NC - ND 4 . 0 I n t e r na t i ona l li c en s e It i s m ade a v a il ab l e unde r a au t ho r / f unde r , w ho ha s g r an t ed m ed R x i v a li c en s e t o d i s p l a y t he p r ep r i n t i n pe r pe t u i t y . i s t he ( w h i c h w as no t p e e r - r e v i e w e d ) T he c op y r i gh t ho l de r f o r t h i s p r ep r i n t . h tt p s : / / do i . o r g / 10 . 1101 / 2020 . 04 . 14 . 20065771 do i : m ed R x i v p r ep r i n t 0 . 00 0 . 02 0 . 04 0 . 06 0 . 08 0 . 10 0 . 12 0 0 . 2 0 . 4 0 . 6 0 . 8 1 20 40 60 80 Age S e r o i n c i den c e S e r op r e v a l en c e Seroincidence : Model 1 Seroincidence : Model 2 Seroincidence : Model 3 Seroincidence : Model 4 Figure 9 : Seroprevalence ( shaded area , scale indicated by right y - axis ) and seroincidence ( lines , scale indicated by left y - axis ) curves by age for a single strain for four hypothetical models of coronavirus immunity : complete homologous immunity ( Model 1 ) , complete homologous immunity for 5 years , then reversion to full susceptibility ( Model 2 ) , partial homologous immunity for life after the first infection ( Model 3 ) , and 4 genotypes within a strain , conferring lifelong genotype - specific immunity but no within - strain cross - immunity ( Model 4 ) . . CC - BY - NC - ND 4 . 0 International license It is made available under a author / funder , who has granted medRxiv a license to display the preprint in perpetuity . is the ( which was not peer - reviewed ) The copyright holder for this preprint . https : / / doi . org / 10 . 1101 / 2020 . 04 . 14 . 20065771 doi : medRxiv preprint